Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN – Dove Medical Press

Yanhai Xi,1,* Tingwang Jiang,2,* Birendra Chaurasiya,3 Yanyan Zhou,1 Jiangmin Yu,1 Jiankun Wen,1 Yan Shen,3 Xiaojian Ye,1 Thomas J Webster4

1Department of Spine Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, Peoples Republic of China; 2Department of Immunology and Microbiology, Institution of Laboratory Medicine of Changshu, Changshu, Jiangsu 215500, Peoples Republic of China; 3Department of Pharmaceutics, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, China Pharmaceutical University, Nanjing, Peoples Republic of China; 4Department of Chemical Engineering, Northeastern University, Boston, MA, USA

*These authors contributed equally to this work

Correspondence: Xiaojian YeDepartment of Spine Surgery, Changzheng Hospital, Second Military Medical University, 360 Huntington Avenue, Shanghai, MA 200003, Peoples Republic of ChinaTel +86 1 381 734 6934Email xjyespine@smmu.edu.cn

Thomas J WebsterDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USATel +1 617 373 6585Email th.webster@neu.edu

Abstract: Ankylosing spondylitis (AS) is a complex disease characterized by inflammation and ankylosis primarily at the cartilagebone interface. The disease is more common in young males and risk factors include both genetic and environmental. While the pathogenesis of AS is not completely understood, it is thought to be an immune-mediated disease involving inflammatory cellular infiltrates, and human leukocyte antigen-B27. Currently, there is no specific diagnostic technique available for this disease; therefore conventional diagnostic approaches such as clinical symptoms, laboratory tests and imaging techniques are used. There are various review papers that have been published on conventional treatment approaches, and in this review work, we focus on the more promising nanomedicine-based treatment modalities to move this field forward.

Keywords: ankylosing spondylitis, pathogenesis, genetic factors, environmental factors, treatment approaches

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read this article:
Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN - Dove Medical Press

Briggs undergrad researcher wins award at international conference – MSUToday

For senior Hasaan Hayat, a Lyman Briggs student with dual majors in neuroscience and human biology, the opportunity to work in a cutting-edge laboratory as an undergraduate researcher both confirmed his interests in technology and medicine and helped illuminate his career path.

For about a year, Hayat has been contributing to research in the lab of Ping Wang, an affiliate with MSUs Precision Health Program, or PHP. Precision medicine, a component of PHP, is a fairly recent field of biomedicine. This field develops personalized, patient-specific therapies and treatments, often incorporating tools like molecular imaging, nanoparticle technology and artificial intelligence to produce better outcomes for patients.

Through research like that of Wang, tools and technologies can be developed to detect disease sooner and treat it earlier, achieving better outcomes and reducing healthcare costs. PHP at MSU aims to transform the approach to healthcare from reactive to proactive by focusing on disease prediction, prevention and early detection.

Hayat has been interested in technology and human biology for as long as he can remember. After he joined Wangs lab, he became especially intrigued by the use of artificial intelligence, or AI, in the field of precision medicine.

As a child, I only dreamed of working on such technology myself due to its complexity and mass potential, but I also feared it, thanks to dystopian films such asTerminatorandiRobotwhere the sentient machine is always portrayed as the bad guy, he said. However, I find that AI can be a crucial, beneficial tool for analysis and monitoring of patients in a more modern field of medicine, specifically in oncology, radiology and stem-cell transplants.

Researching in Wangs lab has provided Hayat a unique platform to investigate the intersection of technology and biology. One specific study involved the application of deep learning in non-invasive imaging for monitoring tumor response to chemotherapy.

With help from Wang and Moore, Hayat put together an abstract of his work titled, Molecular imaging and analysis of uMUC1 expression levels in response to chemotherapy in an orthotopic murine model of ovarian cancer, and submitted it to the World Molecular Imaging Congress 2019, or WMIC 2019, in Montreal, Canada.

The WMIC 2019 program committee invited Hayat to present this research as an oral presentation, which is a high honor for the attendees. Hayats paper was one of the highest-rated abstracts at the conference and he won the Student Travel Award.

Hayat was grateful and energized by the experience of presenting at an international research conference.

The congress was phenomenal. I was able to hear about some amazing research and innovations in the field of medicine and molecular imaging/biology, he said. Networking with knowledgeable individuals from top institutions all over the world was a highlight of the event, and I am thankful to PHP and MSU for this opportunity.

Hayat was originally drawn to MSU for its many research opportunities, and specifically to Lyman Briggs College, because of its solid foundations in science.

I admire Lyman Briggs for its creative and innovative approach to STEM fields, and its focus on preparing students for success in graduate school, he said. The faculty at Lyman Briggs are very supportive and ensure that students have a clear understanding of core scientific concepts.

As for the future, his work with the Precision Health Program is inspiring him to go to medical school.

I aim to pursue an M.D.-Ph.D. after I graduate, a decision that has been heavily reinforced by the research I am doing at the Precision Health Program, and my mentor and PI, Dr. Wang, who himself is an M.D.-Ph.D. I salute the cutting-edge work that is performed here, he said. In the future, it is a dream and vision of mine to bring novel, innovative therapies and technologies such as AI and nanomedicine to the clinic in order to provide tools for physicians to use and to improve patient outcomes.

Visit link:
Briggs undergrad researcher wins award at international conference - MSUToday

What is Nanobots & Its Biggest Contribution in The Medical Industry – Robots.net

Afraid of nanobots rising up and taking over the world? Dont be, that only happens in movies. In the real world, there are types of robots that save the human race, nanorobots to be exact. Experts and professionals are continuously doing extensive research and advanced development in nanotechnology. Research in finding the best uses of nanorobots and nanomachines into the medical industry.

In the field of medicine, theres only a tiny room for error. To be more precise, everything has to be perfect. Of course, professional doctors are highly skilled and knowledgeable to do various surgeries and other treatments to patients. But there are some procedures that require extreme precision that even world-class doctors arent capable of doing.

Imagine a doctor pinpointing cancer cells, or a doctor eliminating the defected parts in someones DNA structure. Those are tasks that are almost impossible to do. But lucky for us, nanorobots and nanomachines exist in our world today. What it does is a guarantee to provide patients with the treatment they need. Hence, giving them a chance to live their lives better and longer.

In this article, well take a deeper look and have a further understanding of what nanobots truly are. We analyze thoroughly from its components, types, to their uses in the medical industry.

Nanorobotics falls under the field of nanotechnology. They deal with the design and development of devices at an atomic, molecular or cellular level. These hypothetical nanorobots are superbly tiny, ranging from 0.1-10 micrometers, capable of traveling inside the human blood. In general, almost all nanorobots have specialized sensors that are able to target molecules. Therefore, it can be programmed to determine and treat targeted diseases.

A nanorobot, also known as nanobot, nanomachines or nanomites, can be made out of different mechanical components. It can be gears or motors using a variety of elements like hydrogen, sulfur, oxygen, nitrogen, silicon and such. On the other hand, the exterior of a nanobot can be created using a diamondoid element due to its dormant characteristics, high thermal conductivity, and durability. They feature extremely smooth surfaces, lessening the possibilities of triggering the bodys immune system.

While an excellent property that nanorobots have is the ability to correlate to each other. Hence, developing a structure with decentralization. Another point is nanobots can do a self-replication process. In which they will create duplicates of themselves and replacing all the non-working units at the same time.

If youre wondering if its possible to communicate with nanorobots, the answer is, yes. All it needs is by encoding messages to acoustic signals at a wave frequency ranging from 1-100 MHz. When the task is completed, these nanorobots can be retrieved through the usual human excretory channels or active scavenger systems can be used.

In constructing nanorobots, there are two main approaches. They are the Positional assembly and the Self-assembly.

In the self-assembly, the nanomachines robotic arm thats used to pick and assemble the molecules are controlled manually by an operator while on the positional assembly, billion of molecules are put together and the nanobots can automatically assemble them into their natural configuration.

Also, nanobots are provided with swarm intelligence for decentralization activity, a technique that was inspired by the behaviors of social animals like ants, bees, etc that can work collaboratively naturally. But in order for the nanobots to function perfectly, they must have these specific components and substructures:

The section where the nanobot holds and releases a small dose of drug/medicine.

The nanorobot may include a miniature camera. The operator can steer the nanorobot when navigating through the body manually

The electrode mounted on the nanorobot could form the battery using the electrolytes in the blood.

These lasers could burn the harmful material like arterial plaque, blood clots or cancer cells.

Use when the nanorobots target and destroy kidney stones.

The nanorobot will need a means of propulsion to get into the body as they travel against the flow of blood in the body.

According to Robert A. Freitas Jr., who has pioneered the study and communication of the benefits to be obtained from advanced nanorobotics and biotechnology, classified nanorobots into three types; Respirocytes, Microbivores, and Clottocytes. He is also responsible for the term Nanomedicine that is commonly used in the field of science today. Lets check out how these three nanobots differ from one another.

First up on our list is the Respirocytes and no, its not the Death Star from Star Wars. Respirocytes are the nanorobots that intend to act as artificial mechanical red blood cells. Its characteristics are the following. First, they are in a spherical blood-borne shape that has 1 micrometer in diameter. Second, it composes of a diamondoid 1000 atm pressure container, the exterior casing. Third, it has reversible molecule-selective pumps.

Respirocytes transport oxygen and carbon dioxide molecules throughout the body. Finally, the respirocyte is a construction of 18 billion atoms. All are accurately arranged in diamondoid pressure tanks. These tanks are capable of storing up to 3 billion oxygen and carbon dioxide molecules. Compared to natural red blood cells, the respirocyte would deliver 236 times more oxygen to the body tissues.

Gas concentration sensors and an onboard nanocomputer can control the respirocyte. Moreover, it manages the carbonic acidity. The stored gases will discharge from the tank in a controlled behavior into the molecular pumps. The respirocytes exchange gases via molecular rotors that have special tips for a particular type of molecule.

Next on our list is the Microbivores. Unlike the Respirocytes, it is an artificial white blood cell that is also known as Nanorobotic Phagocytes.

Microbivores are the nanorobot. It functions as artificial white blood cells and also known as nanorobotic phagocytes. However, this particular nanobot is a spheroid device that consists of a diamond and sapphire. The Microbivers measures 3.4 micrometers in diameter along its major axis and 2.0 micrometers diameter along the minor axis. There are 610 billion of arranged structural atoms are inside the nanobot.

What it does is it traps in the pathogens existing in the bloodstream then breaks down into smaller molecules. While the Microbivores main purpose is to absorb and digest the pathogens in the bloodstream by using the process of phagocytosis. There are four fundamental components of microbivore:

For only 30 seconds, an entire cycle of microbivores phagocytosis will complete. There are no possibilities of septic shock since it has internalized bacterial elements. Also, it digested into non-antigenic biomolecules. The microbivore is 1000 times quicker than antibiotic aided white blood cells. The pathogen also stands no chance of multiple drug resistance.

Taking the third and final spot on our list is the Clottocytes. These nanorobots described as artificial mechanical platelet, designed for Hemostasis. Whats Hemostasis, you say? Let us explain, Hemostasis is the process of blood clotting when theres damage to the endothelium cells of blood vessels by platelets. These platelets will activate by the collision of exposed collagen from damaged blood vessels to the platelets. It will take around 2-5 minutes for the whole process of natural blood clotting.

Clottocytes, on the other hand, can complete the whole process in 1 second approximately. This nanorobot in spherical form is powered by serum-exyglucose. It is about 2 micrometers in diameter and it contains a fiber mesh thats neatly folded inside. When released, the fiber mesh would be biodegradable, a film-like layer of the mesh would disappear in contact with the plasma to reveal the sticky mesh. When compared to the natural hemostatic system, Clottocytes are 100 times if not, 1000 times faster than natural healing.

Nanomites are specifically designed for drug transport called Pharmacytes. The dosage of the drug will load into the payload of the Pharmacyte. And they can precisely transport and target the drug to specific cellular points.

By using nanobots, the patients vitals can be continuously monitored. However, it will lead to a quantum leap in diagnostics.

Dentifrobots are nanorobots that intend for dental treatment. These types of nanomachines can induce oral analgesia, desensitize teeth, manipulate the tissues. Besides, it also uses to realign and straighten irregular sets of teeth.

Nanobot is a program to be self-sufficient onsite surgeons inside the body. Plus, they can do multiple functions. These functions include detecting pathology, diagnosing, correcting lesions. Function coordinated By nano-manipulation by an on-board computer.

Nanorobots are made with a mixture of a polymer. Its transferrin is capable of detecting tumor cells. They feature embedded chemical biosensors, primarily used for detecting tumors

Nanobots carry out glucose molecules into the bloodstream. In order to maintain human metabolism. They use a Chemosensor in which they can modulate the hSGLT3 protein glucose-sensor activity.

Due to the fact that nanorobots can provide better access to the required area, thus it performs micro-surgeries. Moreover, it has extreme precision, they can perform certain surgeries that doctors are not capable of doing.

By medical nanomites, it can treat genetic diseases. Besides, this is by analyzing the molecular composition of DNA and proteins found in the cell. The best part, by using Chromallocytes it can perform Chromosome replacement therapy too.

If nanorobots are really the future of medicine, we are all ready for it. Their precise and efficient performance is definitely something we can rely on. The successful development of Nanobots can unveil new approaches to medical treatment. Hence, resulting in revolutionizing traditional medical treatment that is faster, concise & error-free treatment.

With the constant development and innovation of nanotechnology and nanomedicine, inevitably, more and more of these micrometer nanomachines be developed. Hence, treating more diseases and doing more surgeries, saving more patients in the years to come.

Follow this link:
What is Nanobots & Its Biggest Contribution in The Medical Industry - Robots.net

Anti-Aging and Skin Rejuvenation Energy-Based Aesthetic Devices Market is Poised to Hit $1612.2 Million by 2024: P&S Intelligence – GlobeNewswire

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, the globalanti-aging and skin rejuvenation energy-based aesthetic devices marketwas valued at $872.0 million in 2018, which is projected to reach $1,612.2 million by 2024, progressing at a CAGR of 11.2% during the forecast period (20192024). Based on indication, the skin rejuvenation category is expected to witness faster growth, at a CAGR of 11.5%, during the forecast period, owing to the fact that such devices are more technologically advanced and widely adopted for skin rejuvenating procedures, which is a major reason for the categorys growth.

Based on technology, laser-based devices are expected to hold the largest share, of 28.7%, in the anti-aging and skin rejuvenation energy-based aesthetic devices market in 2024, owing to the rising awareness about the better safety profile of laser-based devices in comparison to treatments based on other types of energy, such as plasma.

Get a Free Sample Copy of this Report at: https://www.psmarketresearch.com/market-analysis/anti-aging-and-skin-rejuvenation-energy-based-aesthetic-devices-market/report-sample

Based on end user, dermatologists/cosmetologists held the largest share, of 54.9%, in 2018 as well as are predicted to record the fastest growth in the global market during the forecast period. This is owing to the surging prevalence of skin diseases and rising awareness about their management through aesthetic procedures.

Direct is likely to be the faster growing distribution channel category, witnessing a CAGR of 11.7%, during the forecast period. This can mainly be ascribed to the growing trend of online shopping, specifically for home-use aesthetic products.

North America is expected to account for the largest share in the anti-aging and skin rejuvenation energy-based aesthetic devices market by 2024, followed by Europe. Together, North America and Europe are expected to account for a 65.3% market share in 2024. This can be mainly attributed to the presence of established players and rising geriatric population, along with the surging consciousness among people about their appearance.

Browse report overview with detailed TOC on"Anti-Aging and Skin Rejuvenation Energy-Based Aesthetic Devices Market Research Report: By Technology (Laser-Based, Light-Based, Electromagnetic Energy-Based, Ultrasound-Based, Plasma Energy-Based), Indication (Skin Rejuvenation, Anti-Aging), Application (Skin Tightening, Fine Line & Wrinkle Reduction, Scar Treatment, Oxygenation), Distribution Channel (Direct, Indirect), End User (Dermatologists/Cosmetologists, Beauticians, Clinicians), Geographical Outlook (U.S., Canada, Italy, Germany, France, Spain, U.K., Japan, India, China, Australia, Brazil, Mexico, Saudi Arabia, South Africa) Global Industry Trends and Growth Forecast to 2024"at: https://www.psmarketresearch.com/market-analysis/anti-aging-and-skin-rejuvenation-energy-based-aesthetic-devices-market

Other regions, which include APAC, LATAM, and MEA, also hold considerable shares in the anti-aging and skin rejuvenation energy-based aesthetic devices market on account of the rapid expansion of the aesthetics industry due to globalization, which is, in turn, increasing the awareness among consumers about alternatives to surgical aesthetic treatments.

In 2018, Japan held a 23.3% share in the APAC market, and it is predicted to prosper at a CAGR of 12.5% during the forecast period. A surge in the aging population and increasing awareness about non-invasive aesthetic procedures are some of the key factors propelling the growth of the market in the country.

Brazil is projected to be the fastest-growing anti-aging and skin rejuvenation energy-based aesthetic devices market in the LATAM region during the forecast period. In Brazil, people are thought of as having the right to beauty. The government supports this right by subsidizing nearly half a million surgeries every year and offering plastic surgeries at public hospitals either for free or at a low cost. Due to the low cost, more people are becoming inclined toward getting these procedures done to enhance their beauty.

Make Enquiry Before Purchase at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=anti-aging-and-skin-rejuvenation-energy-based-aesthetic-devices-market

The anti-aging and skin rejuvenation energy-based aesthetic devices market is fragmented in nature with the presence of giant players, such as Cynosure Inc., Alma Lasers Inc., Syneron Medical Ltd., Lumenis Ltd., Cutera Inc., Solta Medical Inc., Candela Corporation, Sciton Inc., and EL.EN. S.p.A.

The players in the anti-aging and skin rejuvenation energy-based aesthetic devices market are adopting product launches and mergers and acquisitions as a key strategy to maintain their position. For example, in March 2019, Sciton Inc. unveiled the latest version of its flagship platform, JOULE X, at the annual American Society for Laser Medicine and Surgery Meeting (ASLMS), held on March 2731 in Denver, Colorado. JOULE X is a multi-device platform with customizable laser and light performance.

Some other important players operating in the global anti-aging and skin rejuvenation energy-based aesthetic devices market are Allergan Plc, Merz Pharma GmbH & Co. KGaA, Hologic Inc., Bausch Health Companies Inc., Venus Concept Ltd., EndyMed Medical Ltd., LightStim Quasar Biotech Inc., and TRIA Beauty Inc.

More Reports of Life Sciences By P&S Intelligence

MEA Energy-Based Aesthetic Devices MarketSaudi Arabia held the largest share in the MEA energy-based aesthetic devices market in 2018, followed by Turkey. Together, Saudi Arabia and Turkey are expected to account for a 32.4% market share by 2024.

https://www.psmarketresearch.com/market-analysis/mea-energy-based-aesthetic-devices-market

Energy-Based Aesthetic Devices Market

Globally, the North American energy-based aesthetic devices market is expected to account for around 40% share by 2024. This can be mainly attributed to the presence of established players, and increase in the adoption of energy-based aesthetic devices in the region.

https://www.psmarketresearch.com/market-analysis/energy-based-aesthetic-devices-market

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:P&S IntelligenceToll-free: +1-888-778-7886 (USA/Canada)International: +1-347-960-6455Email: enquiry@psmarketresearch.comWeb: https://www.psmarketresearch.com

Connect with us: LinkedIn|Twitter|Facebook

See more here:

Anti-Aging and Skin Rejuvenation Energy-Based Aesthetic Devices Market is Poised to Hit $1612.2 Million by 2024: P&S Intelligence - GlobeNewswire

Unexpected Growth Seen in Medical Aesthetics Market Global Forecast to 2025 with Key Players Allergan PLC, Solta Medical, Syneron Medical, Cynosure…

Medical aesthetics is an area of medicine, dealing with aesthetics, well-being, peripheral appearance, noticeable skin changes, and image of the patient. Medical aesthetics include high-technology skin care procedures that denote the fusion of beauty and healthcare services. Procedures for these include the use of ground-breaking technologies to increase the aesthetics of the person. The demand for anti-aging products and procedures is growing significantly, owing to the growing focus of patients aged 50 years and above to look young and improve their appearance.

Growth in this market is mainly driven by the growing adoption of minimally invasive and noninvasive aesthetic procedures, rising adoption among geriatric individuals, increasing public awareness about cosmetic procedures, the availability of technologically advanced & user-friendly products, and the increasing demand for aesthetic treatments among men.

Get Sample copy of this Report @: https://www.researchnreports.com/request_sample.php?id=77005

Medical Aesthetic Devices Market Key Segments:

Medical Aesthetic Devices Market by Product:

Medical Aesthetic Devices Market by Application:

Medical Aesthetic Devices Market by End User:

Companies Profiled in this Report includes, Allergan PLC, Solta Medical Inc., Syneron Medical Ltd., Cynosure Inc., Lumenis Ltd., Johnson & Johnson, Merz Pharma GmbH & Co., Alma Lasers Ltd.

In product type segment, the aesthetic laser devices are growing at the highest CAGR. Aesthetic laser devices are growing because these lasers work for cosmetics application by a process called selective photothermolysis i.e. the modulation of the frequency of light for the generation of heat in the areas where it is intended to be applied. For achieving the desired aesthetic effect the wavelength of light should perfectly synchronize with the color of the target.

In Application segment, the anti-aging and wrinkles segment is growing with the highest CAGR, because people are more conscious about their look or appearance especially when it comes to their body and hence wrinkles and antiaging application area is dominating the medical aesthetics market as it provides better result in terms of beautiful look.

In the end user segment, the cosmetic centers segment is growing with the highest CAGR because of the high awareness of the people and exclusive cosmetics services are provided in this sector.

Get Discount on this Premium Report @: https://www.researchnreports.com/ask_for_discount.php?id=77005

Key Questions Answered in This Report:

For More Information: https://www.researchnreports.com/enquiry_before_buying.php?id=77005

See the article here:

Unexpected Growth Seen in Medical Aesthetics Market Global Forecast to 2025 with Key Players Allergan PLC, Solta Medical, Syneron Medical, Cynosure...

Hormones Control your Health, Mood and Behavior A balanced hormone means happier, healthier life and success in career and relationship. – Magazine of…

Non-surgical regenerative cell-based treatment uses the bodys natural healing ability to repair damaged bones, muscles, cartilage, tendons and ligaments.Knee injuries are painful and often patients are unable to walk. Our treatment protocol always uses products following FDA guidelines.Injections done with ultrasound guided needle recognition capability to ensure safety as well target the area needing treatment. Plasma; Alpha-2-Macroglobulim (A2M) is the new biologic treatment for your arthritic knee (osteoarthritis)When your hips hurt, or your knee is stiff, or your back is throbbing, that means your joint is bone on bone and there is no lubrication to ease movement.Regenerative medicine giving new hope to patients suffering from painful joint injuries such as knee, shoulder and hip with a chance to live a pain free life.Regenerative cell-based ultrasound guided injection now available to treat pain associated with joint injury. There are indications that it reduces the pain and swelling of the joints and helps lubricating and improve movements.Commonly Treated Conditions: Osteoarthritis of the Hips, Knee, and Shoulders Rotator Cuff tears of the Shoulder Meniscus, ACL and PCL tears of the kneeOur stem cell treatment using your own stem cells and with using imaging guidance ensures precise injection of stem cell, it is a highly-specialized practice.Besides treating above injuries we have advance stem cell micro-needling treatment for the following: Cell-based PRP Hair Restoration combining micro-needling with growth factors and hair follicles voluma vitamins plus BLotinyl T1, Biotin, Anti-aging and Kopexil. Non-toxin facial renewal Anti-Aging APGF Advanced Peptide Micro-needling PRP, Dual Anti-Aging Ampoules for deep hydration, more collagen to reduce wrinkles and firm skin.Dr. Ibrahim is the staff physician at Valencia Medical Center specializing in regenerative medicine, pain management, and rejuvenation. Call for a consultation at 661-222-9117.

See the article here:

Hormones Control your Health, Mood and Behavior A balanced hormone means happier, healthier life and success in career and relationship. - Magazine of...

2.8 million awarded to fund projects by British and Israeli scientists – GOV.UK

The British Council and the British Embassy, Israel, have given the go-ahead to seven, new, three-year bilateral scientific projects in the field of research on ageing. The work will be carried out by top institutions in the UK and Israel.

The projects will be awarded nearly 2.8 million in total from BIRAX, a 10 million programme to support cutting edge UK-Israeli research.

BIRAX Ageing will look at the effects of ageing on human health, and the use of precision medicine and big data in ageing research. It will bring together scientists from the Hebrew University, Hadassah Medical Centre, Tel Aviv University, Tel Aviv Sourasky Medical Centre, University of Oxford, University of Cambridge, Kings College London, and Queens University Belfast.

The projects will focus on various aspects of ageing and how it affects diabetes, vascular disease, neuro-degenerative disease such as Multiple Sclerosis, brain imaging, as well as the use of technology for macular disease research.

British Ambassador to Israel, Mr. Neil Wigan said:

I am excited that seven new projects have been selected for the first call of BIRAX Ageing, the latest phase of our flagship science research programme. These cutting-edge research collaborations not only position the UK and Israel at the forefront of ageing research world-wide, but also reaffirm the close connection between British and Israeli academic communities and establishments. Through these meaningful and sustainable collaborations, we can together tackle universal ongoing challenges.

BIRAX Ageing research looks at the global challenges of ageing, bringing together world-class and complementary scientific capabilities to promote healthy ageing. It aims to establish and grow a substantial new academic community and support ground-breaking collaborative research in the field of ageing, funding both research mobility and joint research projects over the next five years. This crucial research will be generously supported by the Pears Foundation, The Israel Ministry of Science and Technology, The Parasol Foundation Trust, Charles Wolfson Charitable Trust, The Rosetrees Trust, Diabetes UK, The British Heart Foundation, and MS Society.

Sir Trevor Pears, Executive Chair of the Pears Foundation, added:

Since its establishment in 2011, the BIRAX Initiative has earned its excellent reputation for successfully nurturing UKIsrael scientific exchange for the advancement of knowledge. We are proud to have been the founding partner of this important initiative, which will have an enduring impact and legacy, and are delighted to be part of a family of committed partners.

BIRAX was initiated 8 years ago by the British Council, British Embassy in Israel and the UK Science and Innovation Network in collaboration with the Pears Foundation as a founding partner. So far, BIRAX has funded 19 research projects tackling some of the worlds most challenging health conditions and diseases by employing pioneering regenerative medicine and stem cell therapies and using the most advanced and cutting-edge technologies. The ground-breaking science has been made possible through the generous support of a broad family of partners and supporters including the Israel Ministry of Science and Technology, the British Heart Foundation, JDRF, MS Society, Parkinsons UK, Alzheimers Society, the Medical Research Council, The Parasol Foundation Trust, The Rosetrees Trust, Weizmann UK, Clore Foundation Israel, Charles Wolfson Charitable Trust, The Wolfson Foundation, The Maurice and Vivienne Wohl Philanthropic Foundation, The Kahn Foundation, UJIA, Celia and Edward Atkin, The Sheila and Denis Cohen Charitable Trust, The Barbara and Stanley Fink Foundation, and The Glycobiology Institute of Oxford University.

Principal Investigators: Professor Lynne Cox, University of Oxford Professor Rivka Dresner Pollak, Hadassah Medical Center

The overall aim of this research is to understand bone fragility in ageing patients with type 1 diabetes who are currently at high risk of bone fracture and premature death, and to develop new treatments.

Principal Investigators: Professor Heidi Johansen-Berg, University of OxfordProfessor Yaniv Assaf, Tel Aviv University

The project will explore neurodegenerative processes in age related disease such as dementia by understanding the processes behind healthy brain ageing. Owing to dramatic developments in brain imaging methods for providing quantitative measures of brain microstructure, in particular, in Prof Assafs lab in Tel Aviv, these methods could be particularly powerful ways to detect subtle changes in brain structure occurring with ageing, providing early indicators of age-related neurodegeneration. No database of microstructural imaging yet exists.

This project aims to create the first database of microstructural imaging and to initiate a brain database in Israel.

Principal Investigators: Professor Robin Franklin, University of CambridgeDr Amnon Buxboim, Hebrew University of Jerusalem

This project seeks to find answers that will provide clues as to how the effects of age might be reversed therapeutically. It will examine how the brain is able to induce harmful in central nerve system stem cells, and how are the physical signals of the brain transmitted to a central nerve system stem cell to change its function.

Principal Investigators: Professor Manuel Mayr, Kings College London Professor Eli Keshet, Hebrew University of Jerusalem

This project proposes a novel anti-ageing approach to combat age-associated deterioration of vascular function. The knowledge gained in the project will be leveraged for the development of new anti-aging treatments.

Principal Investigators: Professor Masashi Narita, University of Cambridge Professor Ittai Ben-Porath, Hebrew University of Jerusalem

This project addresses in depth the roles of beta-cell senescence in aging and diabetes. The researchers aim to uncover whether beta-cell senescence contributes to, or, alternatively acts to counteract diabetes.

Principal Investigators: Professor Tunde Peto, Queens University Belfast Professor Anat Loewenstein, Tel Aviv University

This project aims to investigate the performance of new automated software algorithms to monitor AMD and detect progression, towards implementation in routine patients management; and to investigate the potential for machine learning to identify factors and biomarkers associated with long-term AMD treatment response.

See more here:

2.8 million awarded to fund projects by British and Israeli scientists - GOV.UK

Asad J. Malik’s AR Studio, 1RIC, Is ScalingTo Ground The Augmented In Reality (Exclusive) – Forbes

Asad J. Malik wearing the HoloLens 2

The studio behind Terminal 3 and A Jesters Tale just inked a seven-figure investment deal, recruited veteran Executive Producer Ela Topcuoglu, and established offices in Los Angeles, CA.

When asked what most excites me about the XR industryparticularly in the wake of industry cool-downs and troughsmy response always circles back to the people who comprise it. Spatial media unite a diverse spectrum of technologies, studies, and art formsand the resulting collection of professionals is equally wide-ranging.

One such person is Asad J. Malik, a director whose holographic narratives have tapped the Augmented Reality format to shape and deepen conversations around immigration, transhumanism, and the ethics of AI.

New industries like XR are spheres where the rules of creation and participation are established in real time, and Malik recognized this early on in his careerproducing holographic work like a Harry Potter HoloLens experience and Holograms from Syria in 2017 from his dorm room at Bennington College in Vermont. Through these experiences, he also launched 1RIC, an AR studio dedicated to holographic narrative content.

In partnership with RYOT, 1RIC was the studio behind festival standouts Terminal 3 and A Jesters Tale, the latter of which featured Poppy and was named the Best Augmented Reality experience at Sundance by The Verge. Each deepened Maliks understanding ofand appreciation forholographic immersive narratives.

During that time, 1RIC was effectively a vehicle for Maliks directorial efforts, with the technical expertise of studio partner Jack Daniel Gerrard, a collaborator since early Bennington days.

Building on the successes of that work, Malik moved to Los Angeles post-graduation this spring and used the summer to establish a larger frameand visionfor the studio.

The first major announcement for 1RIC is a seven-figure investmentthe specifics of which wont be announced until later this year.

1RIC is hardly the first content studio to parlay creative accomplishments to scalability, but the vision and approach indicate possible success vectors for other startups in the industry. Unlike many content or visual effects studios, which seek to showcase a wide range of capability, 1RIC is specifically an AR studioand within that, focused on producing interactive volumetric narratives.

Poppy, Titanic Sinclair and Asad J. Malik on the set of A Jesters Tale at Metastage volumetric ... [+] studio.

In a phone interview with the author, Malik explained how 1RIC will continue to lean into the disruptive potential of AR as a storytelling medium able to match the appetite of its audience.

Our focus is not on commercializing as soon as possible, there are enough people focused on that; in this time of widespread cultural anxiety, we find value in initiating creative chaos, Malik said. Whenever new tech like this comes up, it presents the opportunity to instigate change. The world, especially younger generations, are craving experiential storytelling that moves them and presents ideas that deviate from pre-existing social structures.

For at least the next few projects, 1RICs scope is even narrower, focusing on interactive educational content.

XR content in general is in a proving phasecan any given piece rise up and capture enough of the existing audience to prove financial viability? So far, only a handful major titles have been successful enough to be called a hitor even merit continuing efforts.

Maliks approach began as an impulse to create high-quality narrativesbut as word spread about his projects, this approach also managed to prove financial viability on a small scale. Since Terminal 3 left the festival circuit in 2018, professors and researchers in higher education institutions have been reaching out to license it.

Theres no website or pitch deck or contact, but people somehow find [Terminal 3] and seek me out to license it for universities, Malik said. I was honestly surprised how many people have gone out of their way to show it to their students.

The experience, produced with volumetric capture solution Depthkit, puts participants in the position of an immigration officer screening six different people for entry into the United States. The range of people hoping to license Terminal 3 for practical purposes at universities led Malik to realize that 1RIC could fill a present need.

They show it in game design departments, in journalism classes, in literature... Malik said. These narratives apply to so many verticals in education; we realized we could have an impact by building even more experiences like that.

The disruptive component also means that an AR studio focused in storytelling (and largely documentary) content has the capability of busting social structures that have left out certain voices. And, as an interactive medium, this emphasis on democratizing access also stands to inspire creators among these same populations who traditionally have felt barred from participation.

These funds will allow us to build volumetrically captured interactive characters that take up space in a way that hasnt been possible in the past and bring them to underserved communities, Malik said. Our education projects will end up in schools where kids are on lunch programs, giving them access to these narratives before anyone else.

Volumetric refers to three-dimensional video, captured through stages (such as Intel Studios and Metastagethe latter of which is where 1RIC projects capture content) that have cameras mounted all around subjects.

Where content produced in a game engine is able to offer more by way of realtime interactivity, volumetric video reads to the eye as real rather than computer-generated. In working with holographic narrative over the past three years, Malik has realized that this aspect of reality is vital to his vision with 1RIC.

Our particular brand of storytelling is interactive volumetric narrativespeople who are actually captured in real life, Malik said. Its not generative, but that allows us to focus on narrative and the dramatic arc, which is what we do best.

Within this process of story creation, which Malik says will be largely documentary in approach for its coming projects, volumetrically captured holograms lend an intuitive grounding in reality that, in turn, gives him more flexibility as a director in how he presents stories.

In this time when people have so much anxiety around simulation and fakeness and what is true, we want to present immersive subjects that were capturedwhat they say and do happened in real life, Malik said.

And new innovations to the form are allowing the ability to subtly edit volumetric output to deepen the presence participants feel in an immersive context.

Now we can do things like head-retargeting, so characters look at you with their eyes, Malik said.

By keeping 1RICs focus so narrow, Malik has become one of the worlds premier volumetric directors. As new technologies and updates roll out, 1RIC has a running start in using them not just as experiments, but as powerful narrative tools.

Ela Topcuoglu is joining 1RIC as its Executive Producer

Part of 1RICs scaling involved hiring a bigger team, which now numbers at five, notably including Executive Producer Ela Topcuoglu, who Malik first worked with during her tenure as Manager of Immersive Content Development at RYOT, when she helped produce A Jesters Tale.

Elas experience producing a wide variety of projects, both fiction and nonfiction, is a huge asset to us at 1RIC, Malik said. Shes also very seriously engaged with questions around what it means to live a good life and how immersive media fits into that equation. That is exactly the kind of thinking new mediums need to develop with the most consideration possible.

Topcuoglu cited alignment in mission as a deciding factor in joining 1RIC.

I make it my goal with each project I produce to challenge expectations of how technology can be used to tell an effective story, Topcuoglu said in a statement. That is exactly what 1RIC has done time and time again with their AR work. I look forward to working with Asad as we pave the path for a new generation of storytellers and represent what AR is capable of as a medium.

Jack Daniel Gerrard and Julia Greenburger working in the 1RIC offices.

In addition to increasing the number and scope of projects at 1RIC, Malik also hopes these new offices will serve as a new gathering space in the LA community.

Im excited to have a space like this in Mid-City where we can do events to have real conversations around this stuff, Malik said. Were not a corporation or typical startup eithertheres a lot of power to have important conversations, whether its around the future of volumetric or face filters.

Newly opened 1RIC offices on Venice Blvd in Los Angeles

Ultimately, the ability to spark conversation is the charge of any good artist. But being able to foster ongoing discourse around hard, often unanswerable questions is what colleagues cite as one of the Maliks important talents within the industry.

Having worked with countless XR creators, what makes Asads work so unique is his ability to explore polarizing topics such as AI and immigration with incredible nuance, said Jake Sally, head of immersive development at RYOT. He wraps these complex societal issues into a compelling narrative shell that empowers audiences to learn through interaction, ultimately forcing them to think critically about topics that rarely, if ever, have a simple answer.

More news, such as upcoming projects, investment figures, and event listings at 1RIC offices, is forthcoming later in the year. For more information, visit the studios official website.

Read more:
Asad J. Malik's AR Studio, 1RIC, Is ScalingTo Ground The Augmented In Reality (Exclusive) - Forbes

Rett Syndrome Tied to Altered Protein Levels in Brain in Early Study – Rett Syndrome News

Lack of a functional MeCP2 protein leads toRett syndrome by altering levels of brain proteins associated with energy metabolism and protein regulation, a study in a mouse model suggests.

These altered protein levels might also predict Rett syndromes progression, the investigators said.

The study, Brain protein changes in Mecp2 mouse mutant models: Effects on disease progression of Mecp2 brain specific gene reactivation, was published in theJournal of Proteomics.

Rett syndrome is caused by mutations in the MECP2gene that result in a missing functional MeCP2 protein, a regulator of gene expression. Despite prior studies in animal models, little research has focused on the effects of MeCP2 deficiency in the levels of other proteins in the brain, as well as in Rett syndromes progression.

Researchers from Italy used a mouse model of Rett to address this gap. They did a proteomic analysis of the brains of mice both before and after they developed symptoms, and compared the data to controls withoutMECP2mutations. (Proteomics is the large-scale study of proteins, conducted to draw more global conclusions than possible if assessing proteins one-by-one.)

Results showed abnormal levels of 20 brain proteins in symptomatic mice with Rett syndrome. Twelve of these proteins were overproduced, while eight were at lower levels compared to non-diseased control mice.

Notably, eight (40%) of these 20 proteins were involved in energy metabolism (the process by which cells get energy), and six (30%) were involved in proteostasis, which refers to cellular processes to ensure proper production and folding of proteins.

Presymptomatic mice showed abnormal levels in 18 proteins; 10 at low levels and 8 at high levels compared to controls. Similar to symptomatic mice, these proteins were primarily involved in energy metabolism and proteostasis.

The team then looked at mice that had been engineered to turn the MECP2 gene on in the brain, which was associated with mild symptoms and a longer life than otherwise expected.

By comparing animals lacking functional MeCP2 to mice with so-called MECP2 gene reactivation, the researchers worked to identify the proteins most directly impacted by missing MeCP2.

They found 12 proteins whose levels were normalized by gene reactivation. Seven of these proteins were at low levels and five at high levels without functional MeCP2 protein. Again, most were associated with energy metabolism and proteostasis, while two proteins were involved in how cells respond to oxidants reactive molecules that can damage DNA and cellular structures that is called redox regulation.

Only two of these 12 proteins, PYL2 and SODC, had been previously associated with Rett syndrome via earlier animal model studies that recorded altered levels in the brain.

Our findings suggest that RTT [Rett syndrome] is characterized by a complex metabolic dysfunction strictly related to energy metabolism, proteostasis processes pathways and redox regulation mechanisms, the researchers wrote.

Alteration in the evidenced cellular processes, brain pathways and molecular mechanisms [suggest] the possibility of the use of proteins as predictive biomarkers, they added.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

Read this article:

Rett Syndrome Tied to Altered Protein Levels in Brain in Early Study - Rett Syndrome News

Bulls-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place – On Cancer – Memorial Sloan Kettering

Summary

Doctors and scientists from Memorial Sloan Kettering report on an innovative technique for noninvasively watching where a targeted therapy is going in the body. It also allows them to see how much of the drugreaches the tumor.

Targeted therapy has become an important player in the collection of treatments for cancer. But sometimes its difficult for doctors to determine whether a persons tumor has the right target or how much of a drug is actually reaching it.

A multidisciplinary team of doctors and scientists from Memorial Sloan Kettering has discovered an innovative technique for noninvasively visualizing where a targeted therapy is going in the body. This method can also measure how much of it reaches the tumor. What makes this development even more exciting is that the drug they are studying employs an entirely new approach for stopping cancer growth. The work was published on October 24 in Cancer Cell.

This paper reports on the culmination of almost 15 years of research, says first author Naga Vara Kishore Pillarsetty, a radiochemist in the Department of Radiology. Everything about this drug from the concept to the clinical trials was developed completely in-house at MSK.

Our research represents a new role for the field of radiology in drug development, adds senior author Mark Dunphy, a nuclear medicine doctor. Its also a new way to provide precision oncology.

Our research represents a new role for the field of radiology in drug development.

The drug being studied, called PU-H71, was developed by the studys co-senior author Gabriela Chiosis. Dr. Chiosis is a member of the Chemical Biology Program in the Sloan Kettering Institute. PU-H71 is being evaluated in clinical trials for breast cancer and lymphoma, and the early results are promising.

We always hear about how DNA and RNA control a cells fate, Dr. Pillarsetty says. But ultimately it is proteins that carry out the functions that lead to cancer. Our drug is targeting a unique network of proteins that allow cancer cells to thrive.

Most targeted therapies affect individual proteins. In contrast, PU-H71 targets something called the epichaperome. Discovered and named by Dr. Chiosis, the epichaperome is a communal network of proteins called chaperones.

Chaperone proteins help direct and coordinate activities in cells that are crucial to life, such as protein folding and assembly. The epichaperome, on the other hand, does not fold. It reorganizes the function of protein networks in cancer, which enables cancer cells to survive under stress.

Previous research from Dr. Chiosis and Monica Guzman of Weill Cornell Medicine provided details on how PU-H71 works. The drug targets a protein called the heat shock protein 90 (HSP90). When PU-H71 binds to HSP90 in normal cells, it rapidly exits. But when HSP90 is incorporated into the epichaperome, the PU-H71 molecule becomes lodged and exits more slowly. This phenomenon is called kinetic selectivity. It helps explain why the drug affects the epichaperome. It also explains why PU-H71 appears to have fewer side effects than other drugs aimed at HSP90.

At the same time, this means that PU-H71 works only in tumors where an epichaperome has formed. This circumstanceled to the need for a diagnostic method to determine which tumors carry the epichaperome and, ultimately, who might benefit from PU-H71.

Communal Behavior within Cells Makes Cancers Easier to Target

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.

In the Cancer Cell paper, the investigators report the development of a precision medicine tactic that uses a PET tracer with radioactive iodine. It is called [124I]-PU-H71 or PU-PET. PU-PET is the same molecule as PU-H71 except that it carries radioactive iodine instead of nonradioactive iodine. The radioactive version binds selectively to HSP90 within the epichaperome in the same way that the regular drug does. Ona PET scan, PU-PET displays the location of the tumor or tumors that carry the epichaperome and therefore are likely to respond to the drug. Additionally, when its given along with PU-H71, PU-PET can confirm that the drug is reaching the tumor.

This research fits into an area that is sometimes called theranostics or pharmacometrics, Dr. Dunphy says. We have found a very different way of selecting patients for targeted therapy.

He explains that with traditional targeted therapies, a portion of a tumor is removed with a biopsy and then analyzed. Biopsies can be difficult to perform if the tumor is located deep in the body. Additionally, people with advanced disease that has spread to other parts of the body may have many tumors, and not all of them may be driven by the same proteins. By using this imaging tool, we can noninvasively identify all the tumors that are likely to respond to the drug, and we can do it in a way that is much easier for patients, Dr. Dunphy says.

The researchers explain that this type of imaging also allows them to determine the best dose for each person. For other targeted therapies, doctors look at how long a drug stays in the blood. But that doesnt tell you how much is getting to the tumor, Dr. Pillarsetty says. By using this imaging agent, we can actually quantify how much of the drug will reach the tumor and how long it will stay there.

Plans for further clinical trials of PU-H71 are in the works. In addition, the technology reported in this paper may be applicable for similar drugs that also target the epichaperome.

See more here:

Bulls-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place - On Cancer - Memorial Sloan Kettering

UCI vision scientist Krzysztof Palczewski elected to National Academy of Medicine – UCI News

Irvine, Calif., Oct. 21, 2019 Krzysztof Palczewski, the Irving H. Leopold Chair in Ophthalmology and a professor of physiology & biophysics at the University of California, Irvine, has been elected to the National Academy of Medicine, one of the highest distinctions accorded to professionals in the medical sciences, healthcare and public health. He is one of 100 new U.S.-based members announced today.

The National Academy of Medicine recognizes leaders in diverse fields including health and medicine; the natural, social and behavioral sciences; and beyond. Through its domestic and global initiatives, the academy works to address critical issues in health, medicine and related policy and inspire positive action across sectors.

Congratulations to Dr. Palczewskion this exceptional achievement which illustrates the academic excellence of UCI faculty,said Enrique Lavernia, UCI provost and executive vice chancellor. With the election of Dr. Palczewski to the National Academy of Medicine, UCI is now home to42 members of the National Academies of Sciences, Engineering and Medicine, 35 members of the American Academy of Arts & Sciences, nine members of the National Academy of Inventors, and four members of the National Academy of Education.

I feel deeply honored by the National Academy of Medicine election, Palczewski said. Such recognition reflects on our colleagues, collaborators and trainees who contributed to impactful research on eye diseases. Clearly, this distinction further encourages us to give our very best efforts in the next stage of our research: developing therapeutics against blinding diseases.

The internationally renowned chemist, pharmacologist and vision scientist has made critical additions to the understanding of the molecular basis of age-related macular degeneration and inherited retinal degeneration, illuminating the path toward the creation of new vision treatments.

Palczewski has studied the pharmacology of vision for more than 30 years, and his work has had a tremendous impact on efforts to restore vision in people suffering from retinitis pigmentosa and other congenital mutations that result in blindness.

He is best known for discovering the structure, folding and binding properties of rhodopsin, a light-sensitive photoreceptor protein. His findings profoundly increased comprehension of the molecular basis of vision and the structure of photoreceptor cells in the retina. They also contributed to the ability to originate new molecular therapies for age-related macular degeneration and other retinopathies.

Palczewski came to UCI last year from Case Western Reserve University in Cleveland to establish the Center for Translational Vision Research at the Gavin Herbert Eye Institute, which is part of the UCI School of Medicine. There, he collaborates with a team of noted vision scientists to maximize opportunities to translate insights from basic science investigations into clinical treatments.

He holds 29 issued and nine pending patents and has received several prestigious accolades, including the 2015 Bressler Prize in Vision Science and the inaugural 2014 Beckman-Argyros Award in Vision Research.

In addition, Palczewski is the only person to have won both the Cogan Award (1996) for the most promising young vision scientist and the Friedenwald Award (2014) for continuously outstanding ophthalmology research from the Association for Research in Vision and Ophthalmology. His work has been cited more than 46,000 times, with an h-index impact factor of 115, according to Google Scholar.

Palczewski earned a Ph.D. in biochemistry at the Wrocaw University of Science and Technology in Poland.

About the University of California, Irvine: Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 222 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit http://www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.

More here:

UCI vision scientist Krzysztof Palczewski elected to National Academy of Medicine - UCI News

United States Eating Trends Report 2019: Meat, Dairy, Vegetarian, and Vegan – Overview of Continuity & Changes in Consumer Retail Shopping…

DUBLIN--(BUSINESS WIRE)--The "Eating Trends: Meat, Dairy, Vegetarian, and Vegan" report has been added to ResearchAndMarkets.com's offering.

This Eating Trends report provides a topline data overview of continuity and changes in U.S. consumer retail shopping patterns for meat products, dairy products, and meat & dairy alternatives.

The purchasing, demographic, and psychographic data presented draws on the MRI-Simmons national consumer survey series, primarily referencing the Spring 2019 survey release, but also providing for historical perspective selected data back through Spring 2009.

Trended data and current key demographics are provided for the following topics:

Key Topics Covered

1. Introduction: Scope and Methodology

2. Meat, Poultry, and Seafood Products

3. Dairy Foods & Beverages

4. Vegetarianism, Meat Alternatives, and Dairy Alternatives

List of Tables

For more information about this report visit https://www.researchandmarkets.com/r/j0yajy

See original here:
United States Eating Trends Report 2019: Meat, Dairy, Vegetarian, and Vegan - Overview of Continuity & Changes in Consumer Retail Shopping...

Celebrities who turned vegetarian by choice | Here is a list – Republic World – Republic World

Vegetarianism is nothing but the practice of abstaining from consuming meat and the by-products of animals. It has gained widespread popularity in recent timesand has motivated people to change their eating habits. While everyone is doing their bit to adopt a healthy food practice, Bollywood stars are not lagging behind. Here are some Bollywood stars who have opted out of meat and ceased the consumption of animal by-products, turning into a vegetarian.

Also Read |Virat Kohli Lauds 'The Game Changers' Documentary On Vegetarianism

Famous for his healthy diet practice and untamed physique, Shahid Kapoor is one of the few Bollywood stars who refrain from consuming meat. Kapoor was a part of several animal rights campaigns to raise his voice against animal cruelty. The actor was also felicitated by PETA as Asias Sexiest Vegetarian Man in 2011. In a media interaction, Shahid Kapoor revealed that his father, Pankaj Kapoor motivated him to quit meat consumption.

Also Read | Some Clothing Ideas From Celebrities That You Can Wear For Diwali

New to vegetarianism, Alia Bhatt had reportedly given up meat consumption during the summer. She did so to beat the heat. However, the actor loved her changed eating practice and continuedto avoid meat in her meals. Famous for her love for fitness, Alia Bhatts father, Mahesh Bhatt, too, is a vegetarian by choice.

Also Read | 'Bala': Bollywood Celebrities React To Ayushmann's Latest Trailer

Neha Dhupia has never shied away publically from lending her voice in support of animal rights. Reportedly, the actor believes in eating clean and healthy food and to promote the same, the actorhas been avoiding meat in her meals.Being a former Miss India winner,Neha Dhupia is famous for her fitness regime and diet plans. Duringa media interaction, the actor revealed that turning vegetarian has helpedboost her metabolism. The actor added that she prefers leafy vegetables more than any animal by-product.

Also Read |Star Celebrities Bash Together For War Movie's Success

Get the latest entertainment news from India & around the world. Now follow your favourite television celebs and telly updates. Republic World is your one-stop destination for trending Bollywood news. Tune in today to stay updated with all the latest news and headlines from the world of entertainment.

Read more here:
Celebrities who turned vegetarian by choice | Here is a list - Republic World - Republic World

The top AI lighthouse projects to watch in biopharma – FierceBiotech

So-called lighthouse projectsare typically defined as smallefforts focused on deliverables ina narrow area, designed to establish a pathway for larger enterprises down the line. But as the biopharma industrys digital transformation continues apace, with the rapid acceptance of tools such as artificial intelligence and machine learning, certain projects promise to yield impacts on a much wider scale.

At the same time, AI expertise is being quickly diffused throughout the industry through collaborations, with numerous tech firms offering different approaches and services as drug and device makers shop around for those that best suit their needs.

In just the past few years, biopharma has built a large, interconnected network of partnerships as it aims to transform and digitize its processes to maximize their valueacross everything from molecule design to clinical trial planning, as well as in supply chain, quality control and sales strategies.

In a survey released earlier this month by Optum of 500 healthcare industry leaders and professionals, the number of respondents who said their organizations had an AI implementation strategy in place had increased by nearly 88% compared to the year before.

Additionally, the survey found that organizations plan to spend about $40 million apiece on average on AI-related projects over the next five yearsand half of respondents said they expect to see positive returns on AI investments in three years or less.

Its encouraging to see executives growing trust in, and adoption of, AI to make data more actionable in making the health system work better for everyone, Optum President and COO Dan Schumacher said in a statement, although higher levels of trust in AI were seen in regards to administrative applications compared to clinical ones, and the automation of business processes was ranked higher as a priority.

RELATED: Novartis to put AI on every employee's desk through Microsoft partnership

Still, this sets the stage for potentially rapid adoptions in R&D and care delivery as new methods are validated and become available.

Forming collaborations and partnerships will be paramount, as many companies lack the expertise needed to make the transformation on their own in the coming years. Among medtech companies specifically, a report from Deloitte predicts that the current illness-focused system will be completely overhauled by 2040 and replaced by a proactive one that integrates data to personalize a continuum of care spanning before and after a procedure.

One of the ripest sectors for advancement is in digital pathology and assisting diagnosis. Many research projects aim to use machine learning processes to spot the patterns of diseases or conditions in images or scans. This can help ease the burden on hospital departments by screening chest X-rays, MRI scans, tissue slides or pictures of the eye.

In April 2018, the FDA approved the first medical device in the U.S. to use artificial intelligence to detect cases of diabetic retinopathy, the most common cause of vision loss among people with diabetes. Using digitalimages uploaded from a retinal camera, the AIdubbed IDx-DRcan detect those with more than a mild case of the disease and refer them to a healthcare professional.

RELATED: AstraZeneca enlists artificial intelligence for sales rep coaching

The benefits of automating healthcare and research processes are similar in other areas of medicinenot just in mining data for insightbut also in sharing those insights.

Take the MELLODDY project, for example: short for Machine Learning Ledger Orchestration for Drug Discovery, the initiative hopes to share preclinical data among a network of Big Pharma companies and research partners using a blockchain-based infrastructure to protect confidentiality and proprietary information.

Meanwhile, the newest center of the NIH is working to build a universal translator for medical data, with the goal of bringing together researchers from different fields across the healthcare enterpriseon top of redefining our current definitions of disease based on the findings.

Machine learning can also spot patterns in a flood of data from multiple sources, where certain changes, no matter how small, can herald the onset of Alzheimers disease and dementia. Evidation Health, along with Apple and Eli Lilly, is looking to develop digital biomarkers for neurodegenerative disease by tracking peoples daily routines, device usage and changes in speech.

Using all the information provided by patients from different angles, and then feeding that data back into care delivery to potentially improve outcomes, is where machine learning can excel, and Verb Surgicalthe joint venture between Verily and Johnson & Johnsonaims to use those tenets to drive a new generation of surgery.

RELATED: FDA delivers regulatory guidance on AI software and clinical decision-making aids

Elsewherein the Google/Alphabet sphere, DeepMind has developed an AI program to take on one of the most challenging problems in medical science: predicting protein folding, a mathematical problem that reaches a spectacular number of possibilities. The field once relied on human intuition to solve the puzzle. Now were teaching machines to follow similar instincts.

But the biggest changes will come when these methods, tools and knowledge can be made widely available, and the public-private ATOM consortium is looking to do just that. Spun out of the U.S. governments cancer moonshot efforts, the initiative by GlaxoSmithKline, UC San Francisco and federal research laboratories hosts a series of research projects aimed at accelerating preclinical development to a timeline under one year.

This small handful of projects hopes to have an outsized impactand serve as a beacon for the industry as a whole. Read on below. Conor Hale (email | Twitter)

Read more here:

The top AI lighthouse projects to watch in biopharma - FierceBiotech

Antibiotics with novel mechanism of action discovered – Drug Target Review

A new family of synthetic antibiotics that possess broad anti-Gram-negative antimicrobial activity has been discovered.

Researchers have reported the discovery and characterisation of a new family of synthetic antibiotics that possess broad-spectrum anti-Gram-negative antimicrobial activity.

The research teams were headed by the University of Zurich (UZH) and Polyphor AG, both Switzerland.

The new antibiotics interact with essential outer membrane proteins in Gram-negative bacteria, said John Robinson from the UZH Department of Chemistry, who co-led the study. According to our results, the antibiotics bind to complex fat-like substances called lipopolysaccharides and to BamA, an essential protein of the outer membrane of Gram-negative bacteria.

E. coli cells treated with a novel chimeric peptidomimetic antibiotic. Cells in blue are alive while green cells are already killed by the peptidomimetic. As the antibiotic destroys the integrity of the bacterial membranes, the scientists observed explosive cell lysis (cells indicated by arrows), which leads in the release of DNA (diffuse green) (credit: Matthias Urfer, UZH).

BamA is the main component of the so-called -barrel folding complex (BAM), which is essential for outer membrane synthesis. After targeting this essential outer membrane protein, the antibiotics destroy the integrity of the bacterial membranes and the cells burst.

The outer membrane of Gram-negative bacteria protects the cells from toxic environmental factors, such as antibiotics. It is also responsible for the uptake and export of nutrients and signalling molecules. Despite its critical importance, so far no clinical antibiotics target these key proteins required for outer membrane biogenesis, Robinson continued.

The plan now is to progress one compound into human clinical trials. POL7306, a first lead molecule of the novel antibiotics class, is now in pre-clinical development, added Daniel Obrecht, chief scientific officer at Polyphor and co-head of the work.

Continued here:

Antibiotics with novel mechanism of action discovered - Drug Target Review

Testosterone Replacement Therapy Market Research Study by Porters Five Forces Analysis with CAGR of -2.46% & Forecast to 2023 – Joliet Observer

The Testosterone Replacement Therapy Market Report provides Growth history, Sales channel, Manufacturers profiled in Testosterone Replacement Therapy industry, Market share of product and scope of a region in detail. The Market report also consists of key drivers and limiting factors affect the Testosterone Replacement Therapy Market Growth, Change in industry Trends or challenges faced by Testosterone Replacement Therapy Manufacturers in forecast years.Testosterone Replacement Therapy Market report will help you take well-versed decisions, understand opportunities, plan effective business strategies, plan new projects, analyze drivers and give you a vision on the industry forecast.

GetA Sample PDF Of Report

About this marketIncreased awareness about hypogonadism among the public and primary care physicians will drive the market. Globally, different organizations are working on initiatives to increase patient awareness of hypogonadism and available treatment options. The vendors are actively taking part in the awareness campaign to educate the population about the diagnoses and treatment for hypogonadism. Also, organizations are increase awareness about hypogonadism among medical professionals. They release clinical practice guidelines on testosterone therapy. The testosterone replacement therapy market growth at a CAGR of more than (2%) during the forecast period.

The report splits the global Testosterone Replacement Therapy market into theAmericas, Asia-Pacific, Europe, the Middle East, and Africa Region. The Testosterone Replacement Therapy Market report useful for forecasters, marketers, industry specialists & consultants, sales, product managers, Business Development Advisors, Strategy Advisors, manufactures, potential investors, key executive (CEO and COO) to provides a detailed analysis of the key players in the market which provides a company overview, financial overview, service offering, different strategies used by them, and comprehensive SWOT analysis of

Researcher project Testosterone Replacement Therapy market to grow at a CAGR of -2.46% during the period 2019-2023.

Feel Free to Ask Question Before Purchasing the Report

The worldwide and regional Testosterone Replacement Therapy market elements are precisely explained which helps to understand advancing of business trends, drivers, opportunities, and difficulties for the worldwide Testosterone Replacement Therapy market.

Market Overview

Competitive Landscape

The Porters five forces analysis included in the report educates buyer on the current situations along with anticipated future Testosterone Replacement Therapy market size.

Some of the key topics covered in the report include:

Purchase This Report (Price 2500 USD for a Single-User License)

The CAGR of each segment in the Testosterone Replacement Therapy market along with global market (as a whole) is explained with great ease. Also, global and regional Testosterone Replacement Therapy market supply chain analysis provides vital info about producers, distributers and key end-users in the market. It also explains import-export situations, affecting factors, etc. to fully and deeply reveal market situations.

Table of Contents included in Testosterone Replacement Therapy Market Report PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction- Market outline

PART 05: Market landscape Market overview, Market size, and forecast, Five forces analysis

PART 06: Market segmentation by end-user industry

PART 07: Market segmentation by application

PART 08: Geographical segmentation Testosterone Replacement Therapy market in APAC, Europe, North America & ROW

PART 09: A Decision framework

For More Chapters Click Here

Contact Us:

Be sure to follow us on Linkedin at @ 360 Market Updates for more on growth research of the market.

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +44 203 239 8187/ +1 424 253 0807

Excerpt from:
Testosterone Replacement Therapy Market Research Study by Porters Five Forces Analysis with CAGR of -2.46% & Forecast to 2023 - Joliet Observer

Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and…

You may want to sort out your chronic pain, look and feel younger, or maybe you would like to increase your energy level so you can pursue your goals.

Well, thankfully the team at Richardson Pain & Wellness is ready and able to help you do it, their doctors have many years of experience with custom-made wellness plans suited to each patients individual needs and wants, ensuring that they not only feel renewed in our office but for many years to come. All you have to do is set up an appointment with one of the doctors, and they will help you get started and create a plan to suit your needs and interests.

The pain clinic Richardson offers testosterone replacement therapy and hormone replacement therapy at Richardson. If tests show that you do have low T and you notice the condition taking over your life, then you should consider hormone replacement therapy in Richardson to supplement the bodys production of testosterone to levels of young adulthood.

Furthermore, replacement therapy may lead to desired results, such as greater muscle mass and a stronger sex drive.However, Richardson Pain & Wellness the testosterone therapy to treat low T is vital is surprised to make you aware. Due to the mental and physical risks may develop with self-administered artificial or synthetic testosterone.The testosterone therapy Richardson is suitable for those with low testosterone, call Richardson Pain & Wellness today to schedule a consultation.

Also, Richardson offers the residents of medical weight loss programs Richardson, which they designed with care and precision to suit each patient. So, what does the weight loss program entail? Well, they create a customized diet, exercise plan, and supplement program, they believe it is essential to focus on workingwith their body for weight loss, not against it.

Richardson Pain & Wellness creates a weight loss program that is put together by two doctors alongside a registered dietitian. These professionals have years of experience in the field of wellness and pain management. For instance, Janel Kobza-Chukhman has over 15 years of nutrition counseling experience. A considerable advantage of Richardson Pain & Wellness is that they provide you with all three elements; a diet plan, an exercise plan, and supplements. Whats even better is the result you achieve after all the hard work of keeping to your specified program.

Richardson believes the key to healthy weight loss is following a plan that is specially made for you, and they are proud of the weight-loss programs they provide for their clients.

Contact the Richardson pain clinic today if you would like to book an appointment and have one of their experienced doctors custom make a wellness plan to suit your needs or if you want to start your weight-loss journey today. Ring the clinic on (972) 907-1125, or you can email alignrightchiropractic@gmail.com to schedule an appointment.

Source:https://thenewsfront.com/richardson-pain-wellness-offering-testosterone-replacement-therapy-male-hormone-replacement-therapy-medically-assisted-weight-loss-and-conservative-pain-management-in-richardson-texas/

See original here:
Richardson Pain & Wellness Offering Testosterone Replacement Therapy, Male Hormone Replacement Therapy, Medically Assisted Weight Loss, and...

Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 – Statsflash

The global testosterone replacement therapy market rides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.

Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.

For Right Perspective & Competitive Insights, Request For A Sample Here

For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.

Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.

To Clarify Your Doubts About The Report, Request A Brochure Here

From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.

Visit link:
Testosterone Replacement Therapy Market to Expand at a Healthy 4.2% CAGR from 2016 to 2024 - Statsflash

The Good, the Bad and the Ugly of UFC on ESPN 6 – Sherdog.com

Lauzon turned back time by defeating JonathanPearce. It was the perfect way to say goodbye to the sport forLauzon, who has sustained a great deal of damage over the course ofhis career and stepped into the cage riding a three-fight losingstreak. In front of his beloved Bostonians and with the samesignature violence that makes him a surefire Hall of [emailprotected]#$%&gAwesome candidate, Lauzon big-brothered the up and comer withground-and-pound from a half nelson. While Lauzon was hesitant tocommit to retirement immediately after the fight, UFC PresidentDana White seemed ready to encourage him to end his career on ahigh note. Lauzon turned what looked like a setup match for thenext generation -- Pearce was on a five-fight winning streak thatincluded an appearance on Dana Whites Contender Series and twoothers in Bellator MMA -- into the perfect swan song.

Rosa and Costa entered the arena hoping to the right ship, as bothmen had experienced defeats in their previous outings. In stylepairings that promised fireworks against MannyBermudez and the ironically named BostonSalmon, Rosa and Costa came out in the winning side of thosefireworks. With the exception of KyleBochniak, who was outclassed by an impressively poised SeanWoodson, the city managed to enjoy home-cooked victories. Whilethe UFC has rightfully received criticism for not booking mainevents in locations more appropriate for the fighters, it does agood job of keeping a local feel to the undercards. Results likethis help elevate an otherwise routine event.

Unfortunately for Weidman, the extra 20 pounds on the scale didnothing to resuscitate his career. Reyes heavy hands and technicalacumen proved too steep of a mountain to climb, as the formerchampion fell victim to a backstepping left hand and follow-uphammerfists on the ground. Less than two minutes into the contest,Weidmans light heavyweight campaign came to a screeching halt. Hadthings gone differently, it seemed almost certain that theSerra-Longo Fight Team standout would have been tapped to standopposite Jon Jones in abattle over the light heavyweight title. Say what you will aboutwho would have been favored to win that fight, but Weidman wouldhave added name value to the blue corner that is not readilyavailable at 205 pounds. Similar to when rumors swirled aboutRockhold being fast tracked if he passed his first test in a higherweight class, the potential involving Weidman went unfulfilled andthe dominant champion was left to look elsewhere for a marqueematchup.

A victory over Reyes would have provided a simple answer to thequestion of what was next for Weidman, along with a built-in chanceto redeem the misfortune that has plagued his career in recentyears. Now, another decisive loss puts that question in bold print.There just is not an easy answer for Weidman at this point. Hecould elect to remain at 205 pounds. However, his ceiling seemspretty obvious. The damage he sustained in wars at 185 pounds didnot just magically go away with a move up in weight. Just like wewitnessed with James Vick atUFC Fight Night 161, the leap in weight may have come too late.Should Weidman decide to run it back at middleweight, he will facethe same challenges associated with his inability to absorbpunishment. The top names in the division would be no kinder to hischin, including KelvinGastelum, who managed to hurt Weidman badly before beingsubmitted two years ago. Plus, Weidman would be back to draininghis large frame again.

It seems likely that Weidman and his team will examine what lifeoutside of competition looks like. After being knocked out fivetimes in six fights and nearly suffering the same fate in his lonevictory during that stretch, it looks like we are witnessing theend of a great career.

Hardy has made four appearances inside the Octagon so far. Half ofthose them have gotten bogged down with rule-bending controversy.From a competitive standpoint, those controversies have distractedfrom his clear growth as a fighter under the direction of AmericanTop Team. Now, his taking two puffs from a prescribed inhalerbetween the second and third rounds has taken the conversation awayfrom the things he did right in the cage in Boston.

By adding more elements to his game, Hardy managed to outpoint thestubborn Ben Sosoli.Leg kicks from the outside, effective defensive footwork and theability to do something other than quickly blast his opponent tobits were on display. However, when he used his medication betweenrounds, it called the entire fight into question. Going thedistance for the first time and handling a consistent pace withoutmuch issue would normally something to commend for a fighter whosecareer mainly consists of short circuiting the opposition in quickfashion. How can we rightfully look at Hardy lasting the full 15minutes as a positive if he needed his asthma medication to doso?

The fault does not exclusively rest with Hardy or trainer Din Thomas,who was the primary target of Whites criticism after the fact.Granted, when most athletic commissions only allow water or in somecases an electrolyte-enhanced beverage like Gatorade in the corner,there is no reason to believe that medication that enhancescardiorespiratory function is permissible during a fight. However,the Massachusetts State Athletic Commission did plainly tell Hardyand his team that it was permitted. The level of confusion betweenthe commission (which quickly overturned the decision to ano-contest), UFC Vice President of Regulatory Affairs Marc Ratner,the commentary booth, media and amateur online investigators wastruly bizarre to witness. Is Albuterol allowed between rounds? Whatabout the potential abuse of asthma medication in relation tosports performance? Is Massachusetts clear enough about what is andis not allowed in competition? Why was the fight allowed tocontinue into that pivotal third frame in the first place?

As the infamous 1983 boxing match between Luis Resto and BillyCollins Jr. showed, asthma medication can be used a PED to increasecardio capacity. As the testosterone replacement therapy era of MMAshowed, fighters can and will abuse the use of therapeuticexemptions to gain a competitive edge. It sounds like a recipe fordisaster if the commission does not address this properly.

Clear improvement and two dominant wins from Hardy have beensandwiched between two displays of poor judgment. Those trustedwith overseeing the action in a responsible fashion get a solidfailing grade on clearly communicating the proper rules andhandling discrepancies as they arise. Once again, Hardysperformance inside the cage was overshadowed by other factors.

See the original post:
The Good, the Bad and the Ugly of UFC on ESPN 6 - Sherdog.com

Vulnerability of the industrialized microbiota – Science Magazine

One world, one health

As people increasingly move to cities, their lifestyles profoundly change. Sonnenburg and Sonnenburg review how the shift of recent generations from rural, outdoor environments to urbanized and industrialized settings has profoundly affected our biology and health. The signals of change are seen most strikingly in the reduction of commensal microbial taxa and loss of their metabolic functions. The extirpation of human commensals is a result of bombardment by new chemicals, foodstuffs, sanitation, and medical practices. For most people, sanitation and readily available food have been beneficial, but have we now reached a tipping point? How do we conserve our beneficial symbionts and keep the pathogens at bay?

Science, this issue p. eaaw9255

The collection of trillions of microbes inhabiting the human gut, called the microbiome or microbiota, has captivated the biomedical research community for the past decade. Intimate connections exist between the microbiota and the immune system, central nervous system, and metabolism. The growing realization of the fundamental role that the microbiota plays in human health has been accompanied by the challenge of trying to understand which features define a healthy gut community and how these may differ depending upon context. Such insight will lead to new routes of disease treatment and prevention and may illuminate how lifestyle-driven changes to the microbiota can impact health across populations. Individuals living traditional lifestyles around the world share a strikingly similar microbiota composition that is distinct from that found in industrialized populations. Indeed, lineages of gut microbes have cospeciated with humans over millions of years, passing through hundreds of thousands of generations, and lend credence to the possibility that our microbial residents have shaped our biology throughout evolution. Relative to the traditional microbiota, the industrial microbiota appears to have lower microbial diversity, with major shifts in membership and functions. Individuals immigrating from nonindustrialized to industrialized settings or living at different intermediate states between foraging and industrialization have microbiota composition alterations that correspond to time and severity of lifestyle change. Industrial advances including antibiotics, processed food diets, and a highly sanitized environment have been shown to influence microbiota composition and transmission and were developed and widely implemented in the absence of understanding their effects on the microbiota.

Here, we argue that the microbiota harbored by individuals living in the industrialized world is of a configuration never before experienced by human populations. This new, industrial microbiota has been shaped by recent progress in medicine, food, and sanitation. As technology and medicine have limited our exposure to pathogenic microbes, enabled feeding large populations inexpensively, and otherwise reduced acute medical incidents, many of these advances have been implemented in the absence of understanding the collateral damage inflicted on our resident microbes or the importance of these microbes in our health. More connections are being drawn between the composition and function of the gut microbiota and alteration in the immune status of the host. These relationships connect the industrial microbiota to the litany of chronic diseases that are driven by inflammation. Notably, these diseases spread along with the lifestyle factors that are known to alter the microbiota. While researchers have been uncovering the basic tenets of how the microbiota influences human health, there has been a growing realization that as the industrial lifestyle spreads globally, changes to the human microbiota may be central to the coincident spread of non-communicable, chronic diseases and may not be easily reversed.

We suggest that viewing microbiota biodiversity with an emphasis on sustainability and conservation may be an important approach to safeguarding human health. Understanding the services provided by the microbiota to humans, analogous to how ecosystem services are used to place value on aspects of macroecosystems, could aid in assessing the cost versus benefit of specific microbiota dysfunctions that are induced by different aspects of lifestyle. A key hurdle is to establish the impact of industrialization-induced changes to the microbiota on human health. The severity of this impact might depend on the specifics of numerous factors, including health status, diet, human genotype, and lifestyle. Isolating and archiving bacterial strains that are sensitive to industrialization may be required to enable detailed study of these organisms and to preserve ecosystem services that are unique to those strains and potentially beneficial to human health. Determining a path forward for sustainable medical practices, diet, and sanitation that is mindful of the importance and fragility of the microbiota is needed if we are to maintain a sustainable relationship with our internal microbial world.

Aspects of lifestyle, including those associated with industrialization, such as processed foods, infant formula, modern medicines, and sanitation, can change the gut microbiota. Major questions include whether microbiota changes associated with industrialization are important for human health, if they are reversible, and what steps should be taken to prevent further change while information is acquired to enable an informed cost-versus-benefit analysis. It is possible that a diet rich in whole foods and low in processed foods, along with increased exposure to nonpathogenic microbes, may be beneficial to industrial populations.

The human body is an ecosystem that is home to a complex array of microbes known as the microbiome or microbiota. This ecosystem plays an important role in human health, but as a result of recent lifestyle changes occurring around the planet, whole populations are seeing a major shift in their gut microbiota. Measures meant to kill or limit exposure to pathogenic microbes, such as antibiotics and sanitation, combined with other factors such as processed food, have had unintended consequences for the human microbial ecosystem, including changes that may be difficult to reverse. Microbiota alteration and the accompanying loss of certain functional attributes might result in the microbial communities of people living in industrialized societies being suboptimal for human health. As macroecologists, conservationists, and climate scientists race to document, understand, predict, and delay global changes in our wider environment, microbiota scientists may benefit by using analogous approaches to study and protect our intimate microbial ecosystems.

Ecosystems change. Seasonal or periodic fluctuations may occur over short time scales, trajectories of lasting change can occur over time, and sudden perturbations can result in instability or new stable states. Ecosystems can also reach tipping points at which biodiversity crashes, invasive and opportunistic species take over, and the services expected of the original ecosystem are lost, which may result in further damage and/or extinctions. Each human is an ecosystem composed of thousands of species and trillions of members, the host body of Homo sapiens being just one of those species. Most of these community members are microorganisms that reside in the gut, which is the focus of this article. Sequencing of the microbiota shows that human microbiomes are composed of a stunning array of species and functional diversity. An intricate set of interactions, just now being mapped, connects microbial species within a microbiota to one another and to human biology and is beginning to show how profoundly these microbes influence our health.

The first steps in human microbiota assembly occur upon birth, with microbes vying to colonize environment-exposed surfaces in and on the body. This process is influenced by many factors, including mode of birth, nutrition, environment, infection, and antibiotic exposure (1, 2). Specific taxa of microbes have codiversified with Homo sapiens, consistent with vertical transmission over hundreds of thousands of generations (3). The millions of years of association have provided ample opportunities for our biology and theirs to coevolve (4).

Intimate connections between the microbiota and the human immune system, nervous system, and metabolism have been revealed over the past decade (59). The specific microbes that first colonize the infant gut and the ensuing succession of the community can irreversibly influence mucosal and systemic immune development (10). Orchestrating the assembly of a health-promoting gut microbiota or manipulating a mature community to alter human physiology has vast therapeutic potential, which has captured the attention of the biomedical community. Beyond the importance of the microbiota to human health, recent research has also demonstrated its vulnerability. This ecosystem is susceptible to change by selective forces (11, 12). For example, a single course of one type of antibiotic can decimate and reshape the gut microbiota (13). Exciting research is racing to identify disease treatments using microbiome manipulation, but less focus has been placed on how to protect the microbiota from damage that may be deleterious to human health (14).

The germ theory of disease, formalized in the 1860s by Louis Pasteur, portrayed microbes as an enemy to be controlled and eradicated. The subsequent war on microbes deploying hand washing, sterile surgical techniques, and antibiotics has saved countless lives. In 1900, pneumonia, tuberculosis, and infectious enteritis were the three leading causes of mortality in the United States, accounting for almost one-third of all deaths (15). By the end of the millennium, these infectious disease killers were replaced by chronic diseases, including heart disease, cancer, and stroke, which offered evidence of our ability to effectively manage germs. However, the inverse relationship of infectious and chronic disease rates may share a similar underlying cause. Consistent with tenets of the hygiene hypothesis, limited exposure to microbes may result in defects in immune function and/or regulation, leading to an increasing burden of allergic and autoimmune diseases. In light of our new knowledge about the role of the microbiota in health, the war on microbes likely needs to be reconsidered in less combative terms. The profound success of germ-killing techniques and drugs developed in the past century that have minimal acute side effects has led to overuse. The rise of superbugs that are resistant to antibiotics and chemical bactericides reveals that there is a cost to our war on microbes (16). However, the longer-term and less obvious costs to human health of disrupting the microbiota may come from chronic metabolic and immune diseases. Although intimate, the communities that live in our guts are hard to study, and at present we do not fully understand the health impact of the differences in the microbiota observed between human populations.

Microbiota composition, diversity, and gene content in industrialized peoples vary substantially from that of more traditional rural populations and likely from that of our ancient ancestors, indicating that aspects of our lifestyle are changing our resident microbes (4, 1720). Antibiotics are not the only potential contributor to this effect. Other recent changes in practice, including Caesarean section (C-section) delivery, infant formula, and consumption of industrially produced foods, have all been shown to influence the gut microbiota of humans (2123). Although these technological and medical advances have had undeniable benefits (especially for emergency health care), their implementation and widespread use have occurred without an understanding of their impact on our resident microbial communities. At one extreme, microbiota shifts coincident with industrialization may have no impact (or even a beneficial impact, for example, by removing or reducing microbes with pathogenic potential) on human health and longevity. At the other extreme, the microbiota alterations observed in industrialized populations may be a major contributor to the misregulation of the human immune system that drives chronic inflammation (4, 24). Noncommunicable diseases (NCDs), such as stroke, heart disease, some cancers, chronic kidney disease, diabetes, and dementias, all of which are fueled by chronic inflammation, are associated with the worldwide expansion of industrialized lifestyles and are predicted to create a global health crisis in the coming century (25, 26).

In many ways, the rapid changes experienced by the microbiota of urban humans are analogous to those observed in macroecosystems throughout the world (27). Over time and with tremendous efforts to generate and analyze data, a global scientific consensus has emerged that human-induced climate change will have a devastating impact on Earths species and ecosystems if not curtailed and reversed (28, 29). Likewise, as we become increasingly cognizant of the importance of the microbiota in dictating the duration and extent of our health, it is vital that we reframe our relationship with microbes and use strategies similar to the sustainability and biodiversity conservation efforts under way around the globe. What steps should we take now to protect resident microbes, given the current data and range of possible outcomes?

That the gut ecosystem would change in response to marked lifestyle alterations is not surprising. What is notable is that the microbiota of traditional populations share taxa that have been lost or reduced in individuals living in the industrialized world, which we have termed VANISH (volatile and/or associated negatively with industrialized societies of humans) taxa (Fig. 1A) (30). A study comparing the industrialized microbiota with that of three Nepalese populations living on a gradient from foraging to farming showed the shift in microbiota composition that takes place as populations depart from a foraging lifestyle (31). Intermediate states of lifestyle change toward urbanization are accompanied by less extreme but evident changes in the microbiota (Fig. 1, B and C).

(A) Aggregation of gut microbiota composition from multiple studies separated by principal component analysis of BrayCurtis dissimilarity of 16S rRNA enumerations [adapted from Smits et al. (33)]. Top panel: The first principal component explains 22% of the variation in the data from 18 populations living lifestyles spanning from uncontacted Amerindians in Venezuela (top) to fully industrialized populations in Australia, the United States, Canada, and Ireland (bottom). Bottom panel: Mapping the relative abundance of bacterial families on PCo1 reveals global patterns in the VANISH taxa, which are associated negatively with industrialized societies, and BloSSUM taxa (bloom or selected in societies of urbanization/modernization), such as the Bacteroidaceae and Verrucomicrobia. (B) Heat map adapted from Jha et al. (31) displaying taxa that change across lifestyles in one geographic location (Nepal) of individuals living as foragers (Chepang), settled foragers (Raute, Raji), or agriculturalists (Tharu) versus industrialized individuals in the United States. (C) Model adapted from Jha et al. (31) of strain loss and/or reduction versus gain and/or increase across a lifestyle gradient. Different patterns of changing abundance correspond with specific aspects of lifestyle that change as populations move away from foraging and toward urbanization. The model could also reflect the historical progression of industrialized humans from foraging (Homo sapiens arose ~200,000 to 300,000 years ago) to agriculture (starting 10,000 to 20,000 years ago) to industrialization (starting 100 to 200 years ago).

Similarly, a longitudinal study of individuals immigrating from a Thai refugee camp to the United States showed a loss of VANISH taxa within months of immigrating (32). The longer the immigrants lived in the United States, the more profound the changes. In addition to changes in microbial membership, functional differences in the microbiota correspond to lifestyle. Traditional populations such as the Hadza, a hunter-gatherer group living in Tanzania, like the immigrants from Southeast Asia, harbor microbiota with a larger and more diverse collection of carbohydrate active enzymes (CAZymes) than their industrial counterparts. CAZymes digest complex plant polysaccharides, characteristic of traditional dietary fiber intake (32, 33). By comparison, the microbiota of U.S. residents are enriched in CAZymes that degrade host mucus, which serves as a backup food source for gut microbes when dietary fiber is limited, a hallmark of the industrialized diet (33, 34). The selection of mucus-utilizing bacteria in industrialized populations is evident in the enrichment of Akkermansia muciniphila (a mucin-loving bacterium in the phylum Verrucomicrobia) that was found in a worldwide comparison of industrialized and nonindustrialized microbiomes (Fig. 1A) (33). Whether the loss or reduction of VANISH taxa cause or contribute to the growing burden of NCDs in humans remains to be determined. However, determining the potential importance of VANISH taxa to human biology will require efforts to maintain their diversity before it is lost (35, 36).

We must not forget how the attempted eradication of pathogenic microbes with antibiotics, increased sanitation, and medicalized birth has saved countless lives. Other features of industrialized life, such as the Western diet and infant formula, have added convenience, increased human productivity and met the food demands of a growing population. The development and widespread implementation of these technological advances occurred before there was an understanding of their effect on the microbiota and the significance of the microbiota to human health. One difficulty in understanding the effects of different aspects of industrialization on the human gut microbiota is that so many lifestyle factors covary. Below, we summarize studies that have sought to disentangle facets of the industrialized lifestyle that change the microbiota.

The development and use of antibiotics have accompanied human population growth, industrialization, and rapid technological advances. Antibiotics have become the prototypic factor associated with industrialization that negatively affects the gut microbiota. Antibiotic resistance and increased susceptibility to enteric pathogens are well-known negative effects of antibiotic use. Accumulating data also show that oral antibiotic use has long-term effects on the composition of the gut microbiota (37). Just 5 days of ciprofloxacin was shown to decimate the gut microbial community, which only recovered slowly over the ensuing weeks and months (13). Recoveries were individualized, were incomplete, and differed in their kinetics (13). Similarly, other studies have shown that antibiotics can have a long-term impact on the microbiotaperhaps we should not be surprised because most of these medicines were originally designed to have broad-spectrum effects (38).

For most of human existence, humans consumed food and water laden with microbes, some of which caused disease. But humans also routinely consumed benign bacteria, both through incidental environmental exposure (e.g., from dirt or unsanitized food or on the skin) and from fermented foods (39). The recent shift to consuming largely sterile food and water has likely also influenced the microbiota. For example, the source of drinking water was significantly associated with microbiota composition in the cross-sectional study of Nepalese individuals living on a lifestyle gradient, as well as the Hadza (31). As industrial populations removed microbes from drinking water, the burden of diseases such as cholera and other waterborne illnesses decreased. Recent studies in mice suggest that sanitization in the form of cage cleaning does exacerbate extinctions in the microbiota after perturbation (40). The industrialized human microbiota also bears the hallmarks of sanitation, showing greater interindividual differences in microbiota composition (an indication of less microbe sharing between people) compared with traditional human populations in Papua, New Guinea, where individuals share more bacterial species with one another (20). Risking increased infectious diseases by reducing standards of sanitation would be misguided, but a better understanding of how hygienic practices shape our microbiota and the resulting impact on human health is needed. Restoring the consumption of nondisease-causing microbes may ameliorate diseases that are common among populations that consume sterile food and water (41).

Antibiotics and sanitation are intended to limit exposure to pathogenic microbes, but other practices such as the Western diet and C-section births that are not targeted at microbe control may nevertheless be having a profound effect on the microbiota.

Diet is a major driver of the composition and metabolic output of the microbiota (4244). Humans have shifted from a diet of exclusively wild animals and gathered foods to one of domesticated livestock and agricultural produce (10,000 to 20,000 years ago) to a more recent shift to industrially produced foods, including chemically managed livestock and produce and sterilized, ultraprocessed foods containing preservatives and additives (45, 46). These shifts have resulted in a food supply capable of supporting a growing human population, but perhaps at the cost of the populations health (47).

One notable change to foodstuffs is the unintentional depletion of a major form of sustenance for the microbiota: microbiota-accessible carbohydrates (MACs; the complex carbohydrates found in the dietary fiber of edible plants such as legumes, whole grains, vegetables, nuts, etc.) (42). A high-MAC diet was commonplace when humans exclusively foraged for nutrition, and low-MAC diets have been associated with lower microbiota diversity and poor markers of health in humans and in animal models (4850). The paucity of MACs in the industrialized diet was compensated for by additional protein, simple carbohydrates, and fat, which had the effect of altering the composition and functional output of the microbiota (43, 51). The use of additives such as emulsifiers and non-nutritive sweeteners is pervasive in industrialized food. Both have been shown to alter microbiota composition and promote intestinal inflammation. In addition, emulsifiers promote adiposity and non-nutritive sweeteners alter the metabolic output of the microbiota toward one that resembles that of type 2 diabetics (21, 52).

Small changes to the microbiota have the capacity to amplify over generations. For example, mice fed a low-MAC diet showed reduced microbiota diversity that compounded over generations. Restoration of a high-MAC diet was not sufficient to regain microbiota diversity, which indicated that species within the microbiota had gone extinct during the four-generation length of the experiment (50). In another study, antibiotic treatment of pregnant mice altered the microbiota of the offspring and resulted in metabolic derangement that predisposed the pups to diet-induced obesity (53). Similarly, C-section delivery in humans results in colonization of the infant with microbes derived from skin instead of the mothers vaginal microbiota (54). Acute perturbations from diet, antibiotics, and medical practices could have been propagated over generations and synergized with heightened hygiene and sanitation to result in the population-wide ecosystem reconfigurations observed today. The effects of other factors associated with an industrialized lifestyle on the microbiota, including increased sedentary behavior, stress, exposure to new chemicals (e.g., plastics, herbicides, and pesticides), and social isolation, have only begun to be explored (5557).

It is not a given that the microbiota found in traditional populations, which likely shares more commonality with that of our ancient ancestors, would improve the health of a person living in an industrialized society (4). For example, several members of a traditional gut microbiota, such as parasites, are frank pathogens. Some functions of a traditional microbiota may have beneficial effects in the context of a traditional lifestyle but may not in a more urbanized context. We have simplified these points and recognize that some parasites may confer benefits to human health, but how benefit is defined may depend on context and the individual. For example, parasites that protect against intestinal inflammatory diseases may cause opportunistic infections in immunocompromised individuals (58).

While remaining agnostic about broad connections between change in the microbiota and human health, it is worth considering underlying evolutionary principles that might predict whether microbiota changes are likely to be beneficial, deleterious, or neutral. A very conservative view is that until we have a good understanding of which microbes or communities are beneficial or deleterious, including how context determines this answer, we should recognize that (i) our resident microbes have the potential to affect our health in profound ways and (ii) individual lifestyle and/or medical choices and population-level lifestyle, medical, and dietary choices can change these communities. Similar to early, albeit insufficient, steps to address climate change before the full scope of the problem was understood, such as developing renewable alternatives to fossil fuels, a hedge against potential catastrophe seems warranted. In the case of our gut microbes, acting to minimize unintended loss of biodiversity is likely a wise strategy until we know more. We discuss possible strategies below.

An important question is whether loss or reduction of resident, codiversified microbes and associated functions could have a negative health impact on humans. Some properties of the human microbiota appear to have been stable during much of human evolution before industrialization. It is expected that the combined biology and genome of the human body and its commensal microorganisms would have coevolved to maximize human reproductive success (fitness) during that time (59). Because industrialized humans are interested in a long, healthy life, it is worth asking whether long life is consistent with the reproductive success of early humans. The reproductive success of modern hunter-gatherers corresponds to being long lived (as demonstrated by evidence supporting the patriarch hypothesis); therefore, the components of the microbiome that lived within humans throughout most of our existence as a species likely promote biology consistent with a long, healthy life (60).

From the microbial point of view, a bacterial species is chiefly concerned with making more of itself. Therefore, it is worth considering whether it is possible for members of the microbiota that increase host health and longevity to arise. In other words, the question is not only whether the interests of host and microbiota are aligned (i.e., to promote a long, healthy life of the host), but whether microbes that promote the health and longevity of their hosts are retained and favored over evolutionary time.

Gut-resident microbes that improve host health and life span are most likely to arise when the health-promoting function does not incur a short-term fitness cost to themselves (61, 62). For example, imagine a microbial pathway that not only generates energy for the microbe by fermenting a dietary complex carbohydrate but also produces a fermentation end product that can be absorbed by the host and play beneficial metabolic and/or regulatory roles. These microbes would contribute to host health without incurring a fitness cost and could be selected over time as a result of host fitness, longevity, and transmission to offspring and other individuals. We might expect that loss of these coevolved microbes and associated functions would have a negative health impact.

The industrialized microbiota could be considered better adapted to an industrialized host lifestyle by harboring more resistance to antibiotics and being less proficient at dietary fiber degradation. However, such a microbiota may not be optimized for our health.

Learning how to minimize harm to an ecosystem is an easier prospect than rebuilding one that has deteriorated; however, the realization of an ecosystems importance often only becomes apparent after major change has taken place. In the case of the gut microbiota, we may have to confront the daunting task of reconfiguring an ecosystem that we are just beginning to understand. Biodiverse ecosystems are characterized by complex networks of interactions; delete or add one node and the cascade of changes through the network of interactions can be difficult to anticipate. Predicting ecosystem changes from species reintroduction, such as wolves into Yellowstone National Park, is a challenge long faced by conservation biologists (63, 64) (Fig. 2A).

(A) Gray wolves were introduced into Yellowstone National Park in 1995 to control the swelling elk population (105). The rewilding of Yellowstone set off a trophic cascade that resulted in a decreasing elk population (thereby promoting new growth in aspens), an increase in berries available to bears, and stream morphology changes caused by increased woody plants (64). This provides an example of how wildlife management can be used to restore a more diverse and perhaps functional ecosystem, as well as how reintroduction of species into a habitat can lead to unanticipated changes to that ecosystem. (B) Rewilding of a C. difficileinfected microbiota by FMT results in largely predictable outcomes in host health, but the specifics of the resulting microbiota composition are difficult to predict. (C) Long-term strategies for managing the microbiota include precision approaches of adding defined cocktails of microbes, engineered bacterial species, and improving ecosystem habitat quality. For example, increasing dietary MACs encourages commensal growth and provides fermentation end products such as butyrate to the epithelium, which can help keep oxygen tensions lower in the gut and prevent the growth of facultative anaerobes with pathogenic potential (106).

Fecal microbiota transplantation (FMT) is an example of how ecosystem remodeling through multispecies rewilding can be applied to the gut microbiota. In this procedure, all of the bacterial species of a healthy human donors stool microbiota are introduced into a diseased recipient in an attempt to reconfigure a maladaptive ecosystem (Fig. 2B) (65). FMT has been highly effective in treating Clostridium difficile infection (CDI) refractory to conventional antibiotic-based treatment (66). Although this procedure cures CDI, the addition of hundreds of microbial species into an equally complex, although disrupted, ecosystem results in an unpredictable community that is composed of strains from the donor, recipient, and other sources (67, 68). CDI represents an extreme case of ecosystem disruption; therefore, the lack of precision in dictating the resulting community after ecosystem rewilding is clinically tolerable, as almost any resulting microbiota configuration lacking or minimizing C. difficile is preferred. However, FMTs are not an ideal long-term solution for the treatment of many diseases. In many cases, they are simply ineffective, and in others, the unintended consequences may include transmission of antibiotic-resistant microbes or other infectious agents and the transference of unwanted phenotypes from the donor (69). Gut microbiota rewilding through FMT has currently only been consistently successful for C. difficile cases. Similar to cases of animal reintroduction in macroecosystems, success as defined by the ability of these reintroduced species to thrive has been mixed (70).

Targeted rewilding through discrete changes in habitat quality or the introduction of specific species chosen based on known interactions may be a more predictable and successful approach to ecosystem management in a disrupted gut microbiota. Habitat quality is a key element of success in macroecosystem restoration and is also an important consideration in the gut (71). Ecosystems are made up of interacting species and their physicochemical environment. Factors that influence the suitability of the gut habitat, including temperature, pH, osmolality, redox status, water activity, and chemical and nutrient availability, will likely affect the success of microbiota reconfiguration efforts. Mice chronically infected with C. difficile can be effectively treated using a diet containing MACs. This simple change to habitat quality enabled the recovery of a robust indigenous community and reestablished important functions such as short-chain fatty acid (SCFA) production (72). Diet can also create a niche for a newly introduced microbial strain to colonize. For instance, feeding mice the seaweed polysaccharide porphyran allowed engraftment of a porphyran-utilizing Bacteroides strain (73). This example of engrafting a new species into a microbiota may provide a strategy that can be extended to help targeted rewilding (Fig. 2C).

An additional challenge to managing ecosystems is identifying the features within an ecosystem that are beneficial and thus worthy of conservation. One strategy used by ecologists is to assess the services provided by an ecosystem. Ecosystem services, popularized in the Millennium Ecosystem Assessment, enable value to be placed on different components of an ecosystem (74). For example, if a lake provides fresh drinking water and recreation (swimming, fishing), then pollution of that lake would put those services in jeopardy. Likewise, we can consider the ecosystem services supplied by the gut microbiota (75) (Fig. 3). However, determining whether a microbiota ecosystem service is beneficial is difficult enough in itself, and establishing whether this benefit is universal or specific to a subpopulation of people or even only one individual, a developmental period of life, or during disease or reproduction adds complexity. For example, extraction of calories was an important microbiota ecosystem service rendered in the preindustrialized world, but when eating modern, calorie-dense foods, this service becomes less important.

Identifying the benefits provided by the gut microbiome to human health is one way to determine when the ecosystem is functioning well. (A) List of benefits provided by the gut microbiota. This list is not intended to be comprehensive, and the categorization is only one of many possibilities, but it is presented as a potentially useful framework for conceptualizing how to value specific features of microbiota. (B) Current data suggest that, along with the shift in the composition of the industrialized microbiota, certain services may be lost or out of balance, resulting in suboptimal states of host physiology or disease. A more nuanced understanding of which services are beneficial and in what context will be enabled by longitudinal high-dimensional profiling of microbiome and host biology combined with long-term monitoring of health in humans.

Studying microbiota configurations in different contexts may reveal associations that are positive for human health. For example, work on the gut microbiota in individuals undergoing immunotherapy to treat cancer has shown associations between specific microbiota components and improved outcomes (76). Although many specifics remain to be determined, these findings are consistent with the ability of different microbiotas and their services, such as SCFA production, to alter host immune status and function. Unfortunately, such observational work is usually conducted on people living in industrialized countries and therefore is limited in the microbiota configurations and features that are queried.

If humans have developed a dependence upon microbiota services that have been lost during industrialization, then might reintroduction of these services be analogous to complementing a lost portion of human biology and provide broad benefit? Even if this is not the case, given the recent success of prophylactic antibiotics in low- and middle-income countries in improving health and reducing mortality in children, rewilding the microbiota after treatment using defined key strains may become a standard treatment to aid in ecosystem recovery (77). Should this be the case, then considerations of how to make reintroductions self-sustaining, especially in the face of spreading industrialization, will be important.

The goals of a managed microbiota should be to optimize ecosystem services to prevent disease and improve health and longevity. Optimization requires precise, targeted approaches that consider an individuals genotype, microbiome, or subcategory of disease. Given the large global health impact, strategies to protect the microbiome in all populations should be considered to maximize the palette of microbial and molecular tools available. Efforts are under way to archive the microbial diversity found in the gut of humans around the globe (35, 36). Whether these efforts will result in new therapeutics remains to be seen, but at the very least they provide a time capsule of microbial diversity in a rapidly industrializing world. Industrialization of the microbiome, and its accompanying loss or reduction of certain species, can occur on a time scale of months within an individual, creating some urgency for the banking of vulnerable species (78). An additional challenge is navigating the changing restrictions on the distribution of bacterial strains for research and therapeutic development while protecting the rights and recognizing the contribution of the people from which they came (79, 80).

Reshaping ingrained aspects of industrialized societies to moderate practices that have negative impacts on the microbiota will be a challenge but will be more practical than reversion to preindustrial practices (see Box: Sustainable ecosystem management approaches). Antibiotic use will remain an important aspect of industrial life; however, regulation in clinical and agricultural settings is needed to maintain efficacy and to protect the microbiome. Similarly, rationally engineered microbial cocktails or fermented foods could offer safe microbe exposure to compensate for sanitization. Government subsidies similar to those provided for certain crops could be justified to make MAC-rich and fermented foods cheaper and more widely available. Until food policy reflects the findings of biomedical research, short-term solutions, such as supplementing processed foods with MACs or probiotic bacteria, could provide a gradual progression toward health-optimizing food systems in industrialized countries.

Expanding cohort and interventional studies in humans from a wide representation of humans while simultaneously documenting microbiome and health changes is key for healthy, sustainable microbiota. Numerous associations have been made between the microbiota and human disease, but additional microbiome datasets from longitudinal, prospective observational and interventional studies of humans will provide insight into causal relationships. High-resolution measurements of host biology, including omics approaches and high-dimensional immune profiling, will be important to elucidate the specific lifestyle practices that lead to the most meaningful microbiome changes for human health (44, 81, 82). Animal models informed by human-derived data can be used to perform controlled studies with the goal of developing strategies to rebuild and maintain a healthy microbiota (83).

Some of the specific forces that are bad for Earth appear also to harm our microbiota. For example, animal meat production removes forest habitat for pasture and results in increased methane production. Excessive meat consumption has been coupled to trimethylamine-N-oxide (TMAO) production by the microbiota, and TMAO is a risk factor for cardiovascular events (84). It may be wise to approach climate and health and microbiota sustainability simultaneously to identify solutions that align Earth and human health (i.e., One World, One Health) (85). Given that environmentally sustainable agricultural practices are compatible with producing food generally recognized to promote health, solutions for the planet and human health may be compatible (86). As Earths microbes adapt to our changing environment, we can expect our bodys ecosystem to reflect our external environment in ways that are difficult to anticipate. Determining microbial or molecular equivalents of rewilding will require a much better understanding of community dynamics and hostmicrobiota interactions than we presently have. Continually monitoring and managing a healthy internal ecosystem may be an effective strategy to combat and prevent the litany of chronic diseases that are currently spreading with industrialization.

As we continue to learn of the multitude of benefits afforded by our microbial symbionts, developing alternative strategies to manage microbial ecosystems will enable us to promote short- and long-term public health priorities simultaneously (87). Listed here are a few examples of successes in using beneficial microbes to manage microbial ecosystems.

Sterility in skin-injury repair has been viewed as an important factor in effective wound healing. However, maintaining a sterile wound-healing environment is a difficult prospect considering the exposure of most wounds to the environment (88). Recent evidence suggests that populating wounds with commensal microbes can reduce infections after surgery and minimize the need for antibiotic treatment (89). Similar strategies are also being tested in treating skin conditions including atopic dermatitis (clinical trial NCT03018275) and acute wounds (90).

Health careassociated infections are pervasive in both high- and low-income countries and are a leading cause of death in the United States (91). Germicidal treatments of hospital surfaces are not completely effective, leaving behind dangerous pathogens, some of which can inhabit surfaces for months and also lead to increasing antibiotic resistance. The use of probiotic-containing cleaners can be an effective, alternative method to decontaminate hospital surfaces that does not select for antibiotic-resistant strains (92).

Concerns over increasing antibiotic resistance, consumption of antibiotic-laden meat, and antibiotic-induced reduction of natural resistance to pathogens have led to the exploration of alternatives to antibiotics in livestock. Probiotic use in chickens has resulted in better growth rates, reductions in pathogen load and antibiotic resistance genes, and improved egg quality (93, 94). Probiotics have also been used to prevent infections and improve milk production in dairy cows and to aid growth in beef cattle (95). Use of probiotics is also beneficial in aquaculture, improving water quality, resistance to pathogens, and growth (96).

There is growing evidence that the use of beneficial bacteria is a promising path forward for managing pathogenic microbes in humans (97). Probiotics can reduce the duration and severity of infectious diarrhea and may be an effective alternative to antibiotics in the treatment and prevention of bacterial vaginosis (98, 99). A synbiotic mixture of Lactobacillus plantarum and fructo-oligosaccharides reduced the incidence of sepsis and lowered rates of respiratory tract infection in a cohort of infants from rural India (100). The use of bacteriophage to control pathogens, especially those that are resistant to multiple antibiotics, is another emerging alternative with recent success (101).

Antibiotics are commonly used in cancer treatment to minimize the risk of infection in a patient population with a disrupted immune system. However, in animal models, antibiotic treatment can alter the microbiota in ways that reduce treatment efficacy (102, 103). In fact, specific manipulation of the microbiota improved immunotherapy-based tumor control in a mouse model of melanoma (102, 103). Optimization of the microbiota to optimize immune status, whether augmenting immunotherapy or enabling bone marrow transplantation, will likely be integral to the future treatment of diseases such as cancer.

Given newly acquired data about the importance of early microbiota assembly in the health of the infant, a rethinking of medicalized birth is warranted. A recent pilot study showed that infants delivered by C-section who were seeded with their mothers vaginal microbes developed microbiota more closely resembling those of vaginally delivered infants (104). Future studies are required to determine whether vaginal seeding after C-section delivery provides any lifelong health benefit to the infant.

Acknowledgments: We thank members of the Sonnenburg lab and collaborators for helpful discussions. Funding: This work was supported by the NIH (R01-DK085025 and DP1-AT00989201). J.L.S. is a Chan Zuckerberg Biohub Investigator. Competing interests: The authors declare no conflicts of interest.

View post:

Vulnerability of the industrialized microbiota - Science Magazine